("vaccine") AND ("cancer") AND ("covid") - Search Results

Year	Number of Results
2020	316
2021	1019
2022	1383
2023	995
2024	267

1

COVID-19 mRNA Vaccines: Lessons Learned from the Registrational Trials and Global Vaccination Campaign.

Mead MN, Seneff S, Wolfinger R, Rose J, Denhaerynck K, Kirsch S, McCullough PA. Mead MN, et al. Cureus. 2024 Jan 24;16(1):e52876. doi: 10.7759/cureus.52876. eCollection 2024 Jan. Cureus. 2024. PMID: 38274635 Free PMC article. Retracted. Review.

Our understanding of COVID-19 vaccinations and their impact on health and mortality has evolved substantially since the first vaccine rollouts. Published reports from the original randomized phase 3 trials concluded that the COVID-19 mRNA vaccines could great …

Our understanding of COVID-19 vaccinations and their impact on health and mortality has evolved substantially since the first vacc …

2

IgG4 Antibodies Induced by Repeated Vaccination May Generate Immune Tolerance to the SARS-CoV-2 Spike Protein.

Uversky VN, Redwan EM, Makis W, Rubio-Casillas A. Uversky VN, et al. Vaccines (Basel). 2023 May 17;11(5):991. doi: 10.3390/vaccines11050991. Vaccines (Basel). 2023. PMID: 37243095 Free PMC article. Review.

Less than a year after the global emergence of the coronavirus SARS-CoV-2, a novel vaccine platform based on mRNA technology was introduced to the market. Globally, around 13.38 billion COVID-19 vaccine doses of diverse platforms have been administered. ...

Less than a year after the global emergence of the coronavirus SARS-CoV-2, a novel vaccine platform based on mRNA technology was intr …

3

mRNA vaccine in cancer therapy: Current advance and future outlook.

Li Y, Wang M, Peng X, Yang Y, Chen Q, Liu J, She Q, Tan J, Lou C, Liao Z, Li X. Li Y, et al. Clin Transl Med. 2023 Aug;13(8):e1384. doi: 10.1002/ctm2.1384. Clin Transl Med. 2023. PMID: 37612832 Free PMC article. Review.

Messenger ribonucleic acid (mRNA) vaccines are a relatively new class of vaccines that have shown great promise in the immunotherapy of a wide variety of infectious diseases and cancer. In the past 2 years, SARS-CoV-2 mRNA vaccines have contributed tremendously against SAR …

Messenger ribonucleic acid (mRNA) vaccines are a relatively new class of vaccines that have shown great promise in the immunotherapy of a wi …

4

Autopsy findings in cases of fatal COVID-19 vaccine-induced myocarditis.

Hulscher N, Hodkinson R, Makis W, McCullough PA. Hulscher N, et al. ESC Heart Fail. 2024 Jan 14. doi: 10.1002/ehf2.14680. Online ahead of print. ESC Heart Fail. 2024. PMID: 38221509 Free article. Review.

We performed a systematic review of all published autopsy reports involving COVID-19 vaccination-induced myocarditis through 3 July 2023. All autopsy studies that include COVID-19 vaccine-induced myocarditis as a possible cause of death were included. ...The …

We performed a systematic review of all published autopsy reports involving COVID-19 vaccination-induced myocarditis through 3 July 2 …

5

Prevalence and factors of COVID-19 vaccine refusal among solid cancer patients in China: an application of the health belief model.

Xie Z, Lau JT, Liang Y, Ouyang Q, Chen J, Lin S, Yao K, Hu X, Lin H, Yu Y, Zeng D. Xie Z, et al. Front Public Health. 2023 Aug 3;11:1236376. doi: 10.3389/fpubh.2023.1236376. eCollection 2023. Front Public Health. 2023. PMID: 37601174 Free PMC article.

COVID-19 vaccine refusal among cancer patients during the pandemic period is under-researched. ...Perceived severity of COVID-19 was significant only in the vaccine refusal vs. ever-vaccination model. ...

COVID-19 vaccine refusal among cancer patients during the pandemic period is under-researched. ...Perceived severity of …

6

SARS-CoV-2 infection and COVID-19 vaccination in cancer patients undergoing immune checkpoint inhibitors.

Yang Y, Xu G. Yang Y, et al. Cell Death Dis. 2023 Jun 30;14(6):390. doi: 10.1038/s41419-023-05922-w. Cell Death Dis. 2023. PMID: 37391394 Free PMC article. Review.

Melanoma (47.4%) was a common cancer type in mild cases and lung cancer (71.4%) in severe cases (P = 0.016). ...In fact, the COVID-19 vaccine has been shown to be safe and effective in patients treated with ICIs. ...

Melanoma (47.4%) was a common cancer type in mild cases and lung cancer (71.4%) in severe cases (P = 0.016). ...In fact, the …

7

Review: N1-methyl-pseudouridine (m1psi): Friend or foe of cancer?

Rubio-Casillas A, Cowley D, Raszek M, Uversky VN, Redwan EM. Rubio-Casillas A, et al. Int J Biol Macromol. 2024 Apr 5;267(Pt 1):131427. doi: 10.1016/j.ijbiomac.2024.131427. Online ahead of print. Int J Biol Macromol. 2024. PMID: 38583833 Review.

Due to the health emergency created by SARS-CoV-2, the virus that causes the COVID-19 disease, the rapid implementation of a new vaccine technology was necessary. mRNA vaccines, being one of the cutting-edge new technologies, attracted significant interest and offer …

Due to the health emergency created by SARS-CoV-2, the virus that causes the COVID-19 disease, the rapid implementation of a new v …

8

Modifiers of COVID-19 vaccine efficacy: Results from four COVID-19 prevention network efficacy trials.

Turley CB, Tables L, Fuller T, Sanders LJ, Scott H, Moodley A, Woodward Davis A, Leav B, Miller J, Schoemaker K, Vandebosch A, Sadoff J, Woo W, Cho I, Dunkle LM, Li S, van der Laan L, Gilbert PB, Follmann D, Jaynes H, Kublin JG, Baden LR, Goepfert P, Kotloff K, Gay CL, Falsey AR, El Sahly HM, Sobieszczyk ME, Huang Y, Neuzil KM, Corey L, Grinsztejn B, Gray G, Rouphael N, Luedtke A; COVID-19 Prevention Network CoVPN. Turley CB, et al. Vaccine. 2023 Jul 25;41(33):4899-4906. doi: 10.1016/j.vaccine.2023.06.066. Epub 2023 Jun 23. Vaccine. 2023. PMID: 37385888 Free PMC article. Clinical Trial.

Questions remain regarding the effect of baseline host and exposure factors on vaccine efficacy (VE) across pathogens and vaccine platforms. We report placebo-controlled data from four Phase 3 COVID-19 trials during the early period of the pandemic. ...COV …

Questions remain regarding the effect of baseline host and exposure factors on vaccine efficacy (VE) across pathogens and vaccine …

9

Natural killer cells and BNT162b2 mRNA vaccine reactogenicity and durability.

Graydon EK, Conner TL, Dunham K, Olsen C, Goguet E, Coggins SA, Rekedal M, Samuels E, Jackson-Thompson B, Moser M, Lindrose A, Hollis-Perry M, Wang G, Maiolatesi S, Alcorta Y, Reyes A, Wong M, Ramsey K, Davies J, Parmelee E, Ortega O, Sanchez M, Moller S, Inglefield J, Tribble D, Burgess T, O'Connell R, Malloy AMW, Pollett S, Broder CC, Laing ED, Anderson SK, Mitre E. Graydon EK, et al. Front Immunol. 2023 Aug 25;14:1225025. doi: 10.3389/fimmu.2023.1225025. eCollection 2023. Front Immunol. 2023. PMID: 37711632 Free PMC article.

In this study, we sought to determine if baseline NK cell frequencies, phenotype, or function correlate with antibody responses or inflammatory side effects induced by the Pfizer-BioNTech COVID-19 vaccine (BNT162b2). METHODS: We analyzed serum and peripheral blood m …

In this study, we sought to determine if baseline NK cell frequencies, phenotype, or function correlate with antibody responses or inflammat …

10

Efficacy and Safety of a Protein-Based SARS-CoV-2 Vaccine: A Randomized Clinical Trial.

Mostafavi E, Eybpoosh S, Karamouzian M, Khalili M, Haji-Maghsoudi S, Salehi-Vaziri M, Khamesipour A, Jalali T, Nakhaeizadeh M, Sharifi H, Mansoori Y, Keramat F, Ghodrati S, Javanian M, Doroud D, Omrani MD, Asadi H, Pouriayevali MH, Ghasemian R, Farshidi H, Pourahmad M, Ghasemzadeh I, Mounesan L, Darvishian M, Mirjalili MR, Toledo-Romani ME, Valenzuela-Silva C, Verez-Bencomo V, Gouya MM, Emadi-Koochak H, Haghdoost AA, Biglari A; Soberana Study Group. Mostafavi E, et al. JAMA Netw Open. 2023 May 1;6(5):e2310302. doi: 10.1001/jamanetworkopen.2023.10302. JAMA Netw Open. 2023. PMID: 37133864 Free PMC article. Clinical Trial.

In cohort 1, 461 (3.2%) cases of COVID-19 occurred in the vaccine group and 221 (6.1%) in the placebo group (vaccine efficacy: 49.7%; 95% CI, 40.8%-57.3%) vs 75 (1.6%) and 51 (4.3%) in cohort 2 (vaccine efficacy: 64.9%; 95% CI, 49.7%-59.5%). The incide …

In cohort 1, 461 (3.2%) cases of COVID-19 occurred in the vaccine group and 221 (6.1%) in the placebo group (vaccine ef …

11

The mRNA Vaccine Revolution: COVID-19 Has Launched the Future of Vaccinology.

Ye Z, Harmon J, Ni W, Li Y, Wich D, Xu Q. Ye Z, et al. ACS Nano. 2023 Aug 22;17(16):15231-15253. doi: 10.1021/acsnano.2c12584. Epub 2023 Aug 3. ACS Nano. 2023. PMID: 37535899 Review.

During the COVID-19 pandemic, mRNA (mRNA) vaccines emerged as leading vaccine candidates in a record time. ...

12

COVID-19 Severity and Waning Immunity After up to 4 mRNA Vaccine Doses in 73 608 Patients With Cancer and 621 475 Matched Controls in Singapore: A Nationwide Cohort Study.

Tan WC, Tan JYJ, Lim JSJ, Tan RYC, Lee ARYB, Leong FL, Lee SC, Chai LYA, Tan TT, Malek MIBA, Ong B, Lye DC, Chiew CJ, Chng WJ, Lim ST, Bharwani LD, Tan IB, Sundar R, Tan KB. Tan WC, et al. JAMA Oncol. 2023 Sep 1;9(9):1221-1229. doi: 10.1001/jamaoncol.2023.2271. JAMA Oncol. 2023. PMID: 37440245 Free PMC article.

IMPORTANCE: Despite patients with cancer being at risk of poor outcomes from COVID-19, there are few published studies for vaccine efficacy in this group, with suboptimal immunogenicity and waning vaccine efficacy described in small studies being a con …

IMPORTANCE: Despite patients with cancer being at risk of poor outcomes from COVID-19, there are few published studies for …

13

mRNA vaccination in breast cancer: current progress and future direction.

Jiang XT, Liu Q. Jiang XT, et al. J Cancer Res Clin Oncol. 2023 Sep;149(11):9435-9450. doi: 10.1007/s00432-023-04805-z. Epub 2023 Apr 26. J Cancer Res Clin Oncol. 2023. PMID: 37100972 Free PMC article. Review.

Effective mRNA vaccine design for in vivo function requires consideration of vaccine targets, mRNA structures, transport vectors, and injection routes. This review provides an overview of pre-clinical and clinical data on various mRNA vaccination platforms used for …

Effective mRNA vaccine design for in vivo function requires consideration of vaccine targets, mRNA structures, transport vecto …

14

Drivers and barriers to COVID-19 vaccination in Australians with cancer.

Allan C, Hyatt A, Appathurai A, Crane M, Lim C, Woolstencroft R, Slavin MA, Piper A, Spence D, Teh BW. Allan C, et al. Support Care Cancer. 2023 Jul 21;31(8):479. doi: 10.1007/s00520-023-07942-w. Support Care Cancer. 2023. PMID: 37477843

Just over a third (497, 34.3%) of the respondents were concerned that the vaccine would impact their cancer treatment. CONCLUSION: Overall, participants had positive attitudes toward COVID-19 vaccination and thought it was safe. Findings supported the role of …

Just over a third (497, 34.3%) of the respondents were concerned that the vaccine would impact their cancer treatment. CONCLUS …

15

Assessing the acceptability of COVID-19 vaccine and its booster dose.

Mubarak S, A'aqoulah A, AlGhawrie H, Albalas S, Innab N. Mubarak S, et al. Immun Inflamm Dis. 2023 Sep;11(9):e950. doi: 10.1002/iid3.950. Immun Inflamm Dis. 2023. PMID: 37773710 Free PMC article.

This study aims to assess the acceptability of the COVID-19 vaccine and the factors that impact the intention to take the COVID-19 vaccine and its booster dose. ...After adjustment for significant background characteristics, a significant association b …

This study aims to assess the acceptability of the COVID-19 vaccine and the factors that impact the intention to take the C …

16

Recent advances in mRNA cancer vaccines: meeting challenges and embracing opportunities.

Wang B, Pei J, Xu S, Liu J, Yu J. Wang B, et al. Front Immunol. 2023 Sep 6;14:1246682. doi: 10.3389/fimmu.2023.1246682. eCollection 2023. Front Immunol. 2023. PMID: 37744371 Free PMC article. Review.

Since the successful application of messenger RNA (mRNA) vaccines in preventing COVID-19, researchers have been striving to develop mRNA vaccines for clinical use, including those exploited for anti-tumor therapy. mRNA cancer vaccines have emerged as a promising nov …

Since the successful application of messenger RNA (mRNA) vaccines in preventing COVID-19, researchers have been striving to develop m …

17

The presence of senescent peripheral T-cells is negatively correlated to COVID-19 vaccine-induced immunity in cancer patients under 70 years of age.

Orillard E, Spehner L, Mansi L, Bouard A, Falcoz A, Lepiller Q, Renaude E, Pallandre JR, Vienot A, Kroemer M, Borg C. Orillard E, et al. Front Immunol. 2023 Jun 2;14:1160664. doi: 10.3389/fimmu.2023.1160664. eCollection 2023. Front Immunol. 2023. PMID: 37334387 Free PMC article.

PURPOSE: Cancer patients are at risk of severe COVID-19 infection, and vaccination is recommended. ...While CD4 SIP level had no impact on COVID-19 vaccine efficacy in elderly patients, our results unraveled a possible predictive role for CD4 SIP(high) …

PURPOSE: Cancer patients are at risk of severe COVID-19 infection, and vaccination is recommended. ...While CD4 SIP level had …

18

An assessment of the strategy and status of COVID-19 vaccination in India.

Gupta SL, Goswami S, Anand A, Naman N, Kumari P, Sharma P, Jaiswal RK. Gupta SL, et al. Immunol Res. 2023 Aug;71(4):565-577. doi: 10.1007/s12026-023-09373-5. Epub 2023 Apr 11. Immunol Res. 2023. PMID: 37041424 Free PMC article. Review.

India is one of the leading countries to set clinical trials, production, and administration of COVID-19 vaccination. Recent COVID-19 vaccine tracker record suggests that 12 vaccines are approved in India, including protein subunit, RNA/DNA, non-replicating v …

India is one of the leading countries to set clinical trials, production, and administration of COVID-19 vaccination. Recent COVID …

19

COVID-19 after hematopoietic cell transplantation and chimeric antigen receptor (CAR)-T-cell therapy.

Kampouri E, Hill JA, Dioverti V. Kampouri E, et al. Transpl Infect Dis. 2023 Nov;25 Suppl 1:e14144. doi: 10.1111/tid.14144. Epub 2023 Sep 28. Transpl Infect Dis. 2023. PMID: 37767643 Review.

More than 3 years have passed since Coronavirus disease 2019 (COVID-19) was declared a global pandemic, yet COVID-19 still severely impacts immunocompromised individuals including those treated with hematopoietic cell transplantation (HCT) and chimeric antigen recep …

More than 3 years have passed since Coronavirus disease 2019 (COVID-19) was declared a global pandemic, yet COVID-19 still sev …

20

COVID-19 vaccine uptake trends in SARS-CoV-2 previously infected cancer patients.

Shahid Z, Patrick AL, Wallander ML, Donahue EE, Trufan SJ, Tan AR, Hwang JJ, Burgess EF, Ragon B, Ghosh N, Grunwald MR, Voorhees PM, Copelan EA, Raghavan D. Shahid Z, et al. Vaccine X. 2023 Aug;14:100289. doi: 10.1016/j.jvacx.2023.100289. Epub 2023 Mar 30. Vaccine X. 2023. PMID: 37020982 Free PMC article.

PURPOSE: Cancer patients are at high risk of developing severe illness from SARS-CoV-2 infection, but risk is lowered with receipt of COVID-19 vaccine. ...The objective of this study was to evaluate COVID-19 vaccine uptake trends in cancer …

PURPOSE: Cancer patients are at high risk of developing severe illness from SARS-CoV-2 infection, but risk is lowered with receipt of …

21

How Taiwan has responded to COVID-19 and how COVID-19 has affected Taiwan, 2020-2022.

Lai CC, Lee PI, Hsueh PR. Lai CC, et al. J Microbiol Immunol Infect. 2023 Jun;56(3):433-441. doi: 10.1016/j.jmii.2023.04.001. Epub 2023 Apr 6. J Microbiol Immunol Infect. 2023. PMID: 37061349 Free PMC article. Review.

From January 2020 to December 2022, there was a total of 8,872,955 confirmed COVID-19 cases in Taiwan. In addition, a total of 15,253 COVID-19 related deaths were reported. ...However, COVID-19 exhibited some adverse impacts on the healthcare systems, such as …

From January 2020 to December 2022, there was a total of 8,872,955 confirmed COVID-19 cases in Taiwan. In addition, a total of 15,253 …

22

Cancer Patients' Attitudes Towards the Anti-Covid-19 Vaccine: A Collective Case Study.

Mirandola M, Andreis F, Deori C, Abdel Kader S, Wedenissow AC, Malighetti C, Meriggi F, Zaniboni A. Mirandola M, et al. Rev Recent Clin Trials. 2023 Nov 6. doi: 10.2174/0115748871258981231024103349. Online ahead of print. Rev Recent Clin Trials. 2023. PMID: 37937577

The course of COVID-19 in cancer patients makes them a high priority for vaccination. ...OBJECTIVE: The purpose of the present study was to determine cancer patients' attitudes toward the anti-COVID-19 vaccine. We examined several constructs tha …

The course of COVID-19 in cancer patients makes them a high priority for vaccination. ...OBJECTIVE: The purpose of the present …

23

Identifying modifiable factors associated with COVID-19 vaccine hesitancy and acceptance among cancer patients in Jordan.

AlMasri R, Al Masri M, Darwish R, Ammar K, Safi Y. AlMasri R, et al. Front Oncol. 2023 Nov 28;13:1281994. doi: 10.3389/fonc.2023.1281994. eCollection 2023. Front Oncol. 2023. PMID: 38090484 Free PMC article.

PURPOSE: This cross-sectional study sought to identify and examine the modifiable factors that can help address COVID-19 vaccine hesitancy and acceptance among cancer patients. ...Study results suggest that providing personalized and tailored information abou …

PURPOSE: This cross-sectional study sought to identify and examine the modifiable factors that can help address COVID-19 vaccine …

24

Clinical characteristics and immune profiles of patients with immune-mediated alopecia associated with COVID-19 vaccinations.

Wang CW, Wu MY, Chen CB, Lin WC, Wu J, Lu CW, Chen WT, Wang FY, Hui RC, Chi MH, Chiu TM, Chang YC, Lin JY, Lin YY, Tsai WT, Hung SI, Chung WH. Wang CW, et al. Clin Immunol. 2023 Oct;255:109737. doi: 10.1016/j.clim.2023.109737. Epub 2023 Aug 14. Clin Immunol. 2023. PMID: 37586672

In vitro lymphocyte activation test revealed that granulysin, granzyme B, and IFN-gamma released from the T cells of COVID-19 vaccines-related AA patients could be significantly increased by COVID-19 vaccine excipients (polyethylene glycol 2000 and polysorbat …

In vitro lymphocyte activation test revealed that granulysin, granzyme B, and IFN-gamma released from the T cells of COVID-19 vaccine …

25

Increased neutralization potency and breadth elicited by a SARS-CoV-2 mRNA vaccine forming virus-like particles.

Zhang P, Falcone S, Tsybovsky Y, Singh M, Gopan V, Miao H, Seo Y, Rogers D, Renzi I, Lai YT, Narayanan E, Stewart-Jones G, Himansu S, Carfi A, Fauci AS, Lusso P. Zhang P, et al. Proc Natl Acad Sci U S A. 2023 Jul 18;120(29):e2305896120. doi: 10.1073/pnas.2305896120. Epub 2023 Jul 10. Proc Natl Acad Sci U S A. 2023. PMID: 37428933 Free PMC article.

Vaccines have played a fundamental role in the control of infectious diseases. We previously developed a messenger RNA (mRNA) vaccine against HIV-1 that forms virus-like particles (VLPs) through coexpression of the viral envelope with Gag. Here, we applied the same princip …

Vaccines have played a fundamental role in the control of infectious diseases. We previously developed a messenger RNA (mRNA) vaccine …

26

Continuous freeze-drying of messenger RNA lipid nanoparticles enables storage at higher temperatures.

Meulewaeter S, Nuytten G, Cheng MHY, De Smedt SC, Cullis PR, De Beer T, Lentacker I, Verbeke R. Meulewaeter S, et al. J Control Release. 2023 May;357:149-160. doi: 10.1016/j.jconrel.2023.03.039. Epub 2023 Mar 30. J Control Release. 2023. PMID: 36958400 Free PMC article.

Messenger RNA (mRNA) lipid nanoparticles (LNPs) have emerged at the forefront during the COVID-19 vaccination campaign. Despite their tremendous success, mRNA vaccines currently require storage at deep freeze temperatures which complicates their storage and distribution, a …

Messenger RNA (mRNA) lipid nanoparticles (LNPs) have emerged at the forefront during the COVID-19 vaccination campaign. Despite their …

27

Omicron BA.1 breakthrough infections in inactivated COVID-19 vaccine recipients induced distinct pattern of antibody and T cell responses to different Omicron sublineages.

Guo L, Zhang Q, Zhong J, Chen L, Jiang W, Huang T, Li Y, Zhang Y, Xu L, Wang X, Xiao Y, Wang Y, Dong X, Dong T, Peng Y, Zhang B, Xie Y, Gao H, Shen Z, Ren L, Cheng T, Wang J. Guo L, et al. Emerg Microbes Infect. 2023 Dec;12(1):2202263. doi: 10.1080/22221751.2023.2202263. Emerg Microbes Infect. 2023. PMID: 37037791 Free PMC article.

The adaptive immunity against SARS-CoV-2 prototype strain and Omicron sublineages induced by BA.1 breakthrough infection in vaccinees of inactivated COVID-19 vaccines have not been well characterized. Here, we report that BA.1 breakthrough infection induced mucosal sIgA an …

The adaptive immunity against SARS-CoV-2 prototype strain and Omicron sublineages induced by BA.1 breakthrough infection in vaccinees of ina …

28

Historical Advances in Structural and Molecular Biology and How They Impacted Vaccine Development.

Koff WC, Rappuoli R, Plotkin SA. Koff WC, et al. J Mol Biol. 2023 Jul 1;435(13):168113. doi: 10.1016/j.jmb.2023.168113. Epub 2023 Apr 18. J Mol Biol. 2023. PMID: 37080423 Review.

They have eliminated smallpox from the planet, decreased morbidity and mortality for major infectious diseases like polio, measles, mumps, and rubella, significantly blunted the impact of the COVID-19 pandemic, and prevented viral induced cancers such as cervical cancer …

They have eliminated smallpox from the planet, decreased morbidity and mortality for major infectious diseases like polio, measles, mumps, a …

29

Unpacking COVID-19 Vaccine Attitudes: Exploring Hesitancy and Acceptance Among Undergraduate Students in Bangladesh.

Bhadra A, Podder V, Islam MM, Devnath S, Hafiz I, Chowdhury KJ, Sujon H, Islam MR, Ali FM, Odo TI, Sudrul M, Roy S, Dey A, Hossain F, Kirshan Kumar S, Agarwala A, Kakoly NS. Bhadra A, et al. Cureus. 2023 Nov 28;15(11):e49576. doi: 10.7759/cureus.49576. eCollection 2023 Nov. Cureus. 2023. PMID: 38156187 Free PMC article.

The Oxford Covid-19 Vaccine Hesitancy Scale was used to measure vaccine hesitancy. ...Participants showed low levels of vaccine hesitancy, with a mean score of 10.77 on the Oxford COVID-19 Vaccine Hesitancy Scale. ...

The Oxford Covid-19 Vaccine Hesitancy Scale was used to measure vaccine hesitancy. ...Participants showed low levels of …

30

Antibody response to SARS-CoV-2 WT and Omicron BA.4/5 of inactivated COVID-19 vaccine in patients with lung cancer after second and booster immunization.

Chen C, Dai L, Zheng C, Li H, Li X, Yang M, Gao R, Yao J, Zhang Z, Shi Y, Han X. Chen C, et al. J Hematol Oncol. 2023 May 3;16(1):47. doi: 10.1186/s13045-023-01443-3. J Hematol Oncol. 2023. PMID: 37138279 Free PMC article.

COVID-19 inactivated vaccine-induced humoral responses in patients with lung cancer (LCs) to SARS-CoV-2 wild-type (WT) strain and variants BA.4/5 after the primary 2-dose and booster vaccination remained unknown. ...

COVID-19 inactivated vaccine-induced humoral responses in patients with lung cancer (LCs) to SARS-CoV-2 wild-type (WT) …

31

Vaccine hesitancy in cancer patients: A rapid review.

Butow P, Shaw J, Bartley N, Milch V, Sathiaraj R, Turnbull S, Der Vartanian C. Butow P, et al. Patient Educ Couns. 2023 Jun;111:107680. doi: 10.1016/j.pec.2023.107680. Epub 2023 Feb 24. Patient Educ Couns. 2023. PMID: 36842287 Free PMC article. Review.

INTRODUCTION: Vaccination is a key strategy to limit the impact of the COVID-19 pandemic, among vulnerable groups such as cancer patients. However, COVID-19 vaccine hesitancy is limiting vaccination uptake in this population as in others. ...

INTRODUCTION: Vaccination is a key strategy to limit the impact of the COVID-19 pandemic, among vulnerable groups such as cancer …

32

COVID-19 and Other Viral Infections in Patients With Hematologic Malignancies.

Harris CE, Vijenthira A, Ong SY, Baden LR, Hicks LK, Baird JH. Harris CE, et al. Am Soc Clin Oncol Educ Book. 2023 May;43:e390778. doi: 10.1200/EDBK_390778. Am Soc Clin Oncol Educ Book. 2023. PMID: 37163714 Free article.

COVID-19 and our armamentarium of strategies to combat it have evolved dramatically since the virus first emerged in late 2019. ...NR interacts with many blood cancer treatments, and reviewing drug interactions is essential. Patients with severe COVID-19 shou …

COVID-19 and our armamentarium of strategies to combat it have evolved dramatically since the virus first emerged in late 2019. ...NR …

33

Cancer vaccine strategies using self-replicating RNA viral platforms.

Dailey GP, Crosby EJ, Hartman ZC. Dailey GP, et al. Cancer Gene Ther. 2023 Jun;30(6):794-802. doi: 10.1038/s41417-022-00499-6. Epub 2022 Jul 12. Cancer Gene Ther. 2023. PMID: 35821284 Free PMC article. Review.

The development and success of RNA-based vaccines targeting SARS-CoV-2 has awakened new interest in utilizing RNA vaccines against cancer, particularly in the emerging use of self-replicating RNA (srRNA) viral vaccine platforms. ...As such, while this remains an act …

The development and success of RNA-based vaccines targeting SARS-CoV-2 has awakened new interest in utilizing RNA vaccines against cancer …

34

SARS-CoV-2 Infection, Hospitalization, and Mortality in Adults With and Without Cancer.

Hosseini-Moghaddam SM, Shepherd FA, Swayze S, Kwong JC, Chan KKW. Hosseini-Moghaddam SM, et al. JAMA Netw Open. 2023 Aug 1;6(8):e2331617. doi: 10.1001/jamanetworkopen.2023.31617. JAMA Netw Open. 2023. PMID: 37651139 Free PMC article.

IMPORTANCE: Patients with cancer are at increased risk of SARS-CoV-2-associated adverse outcomes. ...However, the risk of 21-day ICU admission in patients with hematologic malignant neoplasms (aHR, 1.14; 95% CI, 0.93-1.40) or solid tumors (aHR, 0.93; 95% CI, 0.82-1.05) was …

IMPORTANCE: Patients with cancer are at increased risk of SARS-CoV-2-associated adverse outcomes. ...However, the risk of 21-day ICU …

35

COVID-19 vaccine hesitancy and attitudes in Pakistan: a cross-sectional phone survey of major urban cities.

Khan AA, Abdullah M, Aliani R, Mohiuddin AF, Sultan F. Khan AA, et al. BMC Public Health. 2023 Jun 9;23(1):1112. doi: 10.1186/s12889-023-15905-3. BMC Public Health. 2023. PMID: 37296386 Free PMC article.

Vaccine distribution to achieve herd immunity is hindered by hesitance and negative attitude of the public against COVID-19 vaccination. ...CONCLUSIONS: Although our study found 35% hesitancy rate of COVID-19 vaccine, there were noticeable demographic …

Vaccine distribution to achieve herd immunity is hindered by hesitance and negative attitude of the public against COVID-19 va …

36

Health Literacy and COVID-19 Vaccination among Cancer Patients in Northeastern Thailand: A Cross-Sectional Study.

Dapha P, Phimha S, Prasit N, Senahad N. Dapha P, et al. Asian Pac J Cancer Prev. 2023 Jul 1;24(7):2375-2381. doi: 10.31557/APJCP.2023.24.7.2375. Asian Pac J Cancer Prev. 2023. PMID: 37505769 Free PMC article.

OBJECTIVE: This study aimed to explore factors associated with COVID-19 vaccine uptake among patients with cancer in northeastern Thailand. ...It could influent a higher rate of vaccine uptake among patients with cancer....

OBJECTIVE: This study aimed to explore factors associated with COVID-19 vaccine uptake among patients with cancer in no …

37

Safety and immunogenicity of a third dose of mRNA-1273 vaccine among cancer patients.

Giuliano A, Kuter B, Pilon-Thomas S, Whiting J, Mo Q, Leav B, Sirak B, Cubitt C, Dukes C, Isaacs-Soriano K, Kennedy K, Ball S, Dong N, Jain A, Hwu P, Lancet J. Giuliano A, et al. Cancer Commun (Lond). 2023 Jul;43(7):749-764. doi: 10.1002/cac2.12453. Epub 2023 Jun 28. Cancer Commun (Lond). 2023. PMID: 37377402 Free PMC article.

METHODS: The mRNA-1273 vaccine was administered 7 to 9 months after administering two vaccine doses (i.e., the primary series). ...Lymphoid cancer patients experienced lower humoral responses to dose three of the mRNA-1273 vaccine, suggesting that time …

METHODS: The mRNA-1273 vaccine was administered 7 to 9 months after administering two vaccine doses (i.e., the primary series) …

38

A review of HPV and HBV vaccine hesitancy, intention, and uptake in the era of social media and COVID-19.

Vraga EK, Brady SS, Gansen C, Khan EM, Bennis SL, Nones M, Tang R, Srivastava J, Kulasingam S. Vraga EK, et al. Elife. 2023 Aug 18;12:e85743. doi: 10.7554/eLife.85743. Elife. 2023. PMID: 37594016 Free PMC article. Review.

However, the association between COVID-related vaccine hesitancy and cancer vaccines such as HPV is unclear. ...and (2) Is exposure to COVID-19 vaccine misinformation on social media associated with HPV or HBV vaccine hesitancy, intention …

However, the association between COVID-related vaccine hesitancy and cancer vaccines such as HPV is unclear. ...and (2) …

39

Vaccine development: Current trends and technologies.

Poria R, Kala D, Nagraik R, Dhir Y, Dhir S, Singh B, Kaushik NK, Noorani MS, Kaushal A, Gupta S. Poria R, et al. Life Sci. 2024 Jan 1;336:122331. doi: 10.1016/j.lfs.2023.122331. Epub 2023 Dec 7. Life Sci. 2024. PMID: 38070863 Review.

These advancements have also greatly enhanced our understanding of vaccine immunology, which will guide future vaccine development for a broad range of diseases, including rapidly emerging infectious diseases like COVID-19 and diseases that have historically …

These advancements have also greatly enhanced our understanding of vaccine immunology, which will guide future vaccine develop …

40

SARS-CoV-2 Vaccine Safety and Autoimmune Response.

Tyan YC, Chuang SC, Ho TC, Chuang KP, Yang MH. Tyan YC, et al. Vaccines (Basel). 2024 Mar 20;12(3):334. doi: 10.3390/vaccines12030334. Vaccines (Basel). 2024. PMID: 38543968 Free PMC article.

Coronavirus disease 2019 (COVID-19) is a global public health crisis [...]....

41

Anti-S and Anti-N Antibody Responses of COVID-19 Vaccine Recipients.

Al-Shudifat AE, Al-Tamimi M, Dawoud R, Alkhateeb M, Mryyian A, Alahmad A, Abbas MM, Qaqish A. Al-Shudifat AE, et al. Vaccines (Basel). 2023 Aug 22;11(9):1398. doi: 10.3390/vaccines11091398. Vaccines (Basel). 2023. PMID: 37766076 Free PMC article.

Individuals who were infected with COVID-19 after receiving the vaccine demonstrated higher levels of anti-N IgG, exhibiting a 25% increase in mean titer levels compared to those who were infected prior to vaccination. ...Smokers had a low positivity rate of anti-N …

Individuals who were infected with COVID-19 after receiving the vaccine demonstrated higher levels of anti-N IgG, exhibiting a …

42

COVID-19 booster vaccination during pregnancy enhances maternal binding and neutralizing antibody responses and transplacental antibody transfer to the newborn.

Munoz FM, Posavad CM, Richardson BA, Badell ML, Bunge KE, Mulligan MJ, Parameswaran L, Kelly CW, Olson-Chen C, Novak RM, Brady RC, Pasetti MF, Defranco EA, Gerber JS, Shriver MC, Suthar MS, Coler RN, Berube BJ, Kim SH, Piper JM, Miller AM, Cardemil CV, Neuzil KM, Beigi RH; DMID 21-0004 Study Group. Munoz FM, et al. Vaccine. 2023 Aug 14;41(36):5296-5303. doi: 10.1016/j.vaccine.2023.06.032. Epub 2023 Jun 13. Vaccine. 2023. PMID: 37451878 Free PMC article.

The immune response to COVID-19 booster vaccinations during pregnancy for mothers and their newborns and the functional response of vaccine-induced antibodies against Omicron variants are not well characterized. ...A booster dose during pregnancy significantly incre …

The immune response to COVID-19 booster vaccinations during pregnancy for mothers and their newborns and the functional response of …

43

Morphologic and molecular analysis of liver injury after SARS-CoV-2 vaccination reveals distinct characteristics.

Uzun S, Zinner CP, Beenen AC, Alborelli I, Bartoszek EM, Yeung J, Calgua B, Reinscheid M, Bronsert P, Stalder AK, Haslbauer JD, Vosbeck J, Mazzucchelli L, Hoffmann T, Terracciano LM, Hutter G, Manz M, Panne I, Boettler T, Hofmann M, Bengsch B, Heim MH, Bernsmeier C, Jiang S, Tzankov A, Terziroli Beretta-Piccoli B, Matter MS. Uzun S, et al. J Hepatol. 2023 Sep;79(3):666-676. doi: 10.1016/j.jhep.2023.05.020. Epub 2023 Jun 7. J Hepatol. 2023. PMID: 37290592 Free PMC article.

Little is known about the pathophysiology of COVID-19 vaccine-induced liver injury (VILI) and its relationship to AIH. ...IMPACT AND IMPLICATIONS: Little is known about the pathophysiology of COVID-19 vaccine-induced liver injury (VILI). Our analysis s …

Little is known about the pathophysiology of COVID-19 vaccine-induced liver injury (VILI) and its relationship to AIH. ...IMPA …

44

Concomitant administration of seasonal influenza and COVID-19 mRNA vaccines.

Aydillo T, Balsera-Manzanero M, Rojo-Fernandez A, Escalera A, Salamanca-Rivera C, Pachón J, Del Mar Muñoz-García M, Sánchez-Cordero MJ, Sánchez-Céspedes J, García-Sastre A, Cordero E. Aydillo T, et al. Emerg Microbes Infect. 2024 Dec;13(1):2292068. doi: 10.1080/22221751.2023.2292068. Epub 2024 Jan 18. Emerg Microbes Infect. 2024. PMID: 38054302 Free PMC article.

Current clinical guidelines support the concomitant administration of seasonal influenza vaccines and COVID-19 mRNA boosters vaccine. Whether dual vaccination may impact vaccine immunogenicity due to an interference between influenza or SARS-CoV-2 antigens is …

Current clinical guidelines support the concomitant administration of seasonal influenza vaccines and COVID-19 mRNA boosters vacci …

45

A microneedle vaccine printer for thermostable COVID-19 mRNA vaccines.

Vander Straeten A, Sarmadi M, Daristotle JL, Kanelli M, Tostanoski LH, Collins J, Pardeshi A, Han J, Varshney D, Eshaghi B, Garcia J, Forster TA, Li G, Menon N, Pyon SL, Zhang L, Jacob-Dolan C, Powers OC, Hall K, Alsaiari SK, Wolf M, Tibbitt MW, Farra R, Barouch DH, Langer R, Jaklenec A. Vander Straeten A, et al. Nat Biotechnol. 2024 Mar;42(3):510-517. doi: 10.1038/s41587-023-01774-z. Epub 2023 Apr 24. Nat Biotechnol. 2024. PMID: 37095347

Decentralized manufacture of thermostable mRNA vaccines in a microneedle patch (MNP) format could enhance vaccine access in low-resource communities by eliminating the need for a cold chain and trained healthcare personnel. Here we describe an automated process for printin …

Decentralized manufacture of thermostable mRNA vaccines in a microneedle patch (MNP) format could enhance vaccine access in low-resou …

46

Effectiveness and safety of COVID-19 vaccines in patients with oncological diseases: State-of-the-art.

Ivanov N, Krastev B, Miteva DG, Batselova H, Alexandrova R, Velikova T. Ivanov N, et al. World J Clin Oncol. 2023 Sep 24;14(9):343-356. doi: 10.5306/wjco.v14.i9.343. World J Clin Oncol. 2023. PMID: 37771630 Free PMC article. Review.

Indeed, patients with oncohematological diseases have a higher risk of severe COVID-19 and impaired post-vaccination immunity. Unfortunately, cancer patients are usually excluded from vaccine trials and investigations of post-vaccinal immune responses and the …

Indeed, patients with oncohematological diseases have a higher risk of severe COVID-19 and impaired post-vaccination immunity. Unfort …

47

Research progress in spike mutations of SARS-CoV-2 variants and vaccine development.

He X, He C, Hong W, Yang J, Wei X. He X, et al. Med Res Rev. 2023 Jul;43(4):932-971. doi: 10.1002/med.21941. Epub 2023 Mar 16. Med Res Rev. 2023. PMID: 36929527 Review.

The coronavirus disease 2019 (COVID-19) pandemic can hardly end with the emergence of different variants over time. ...Moreover, the vaccine effectiveness of current COVID-19 vaccines against SARS-CoV-2 VOCs is not as high as that against wild-type SARS-CoV-2 …

The coronavirus disease 2019 (COVID-19) pandemic can hardly end with the emergence of different variants over time. ...Moreover, the …

48

SARS-CoV-2-specific immune responses and clinical outcomes after COVID-19 vaccination in patients with immune-suppressive disease.

Barnes E, Goodyear CS, Willicombe M, Gaskell C, Siebert S, I de Silva T, Murray SM, Rea D, Snowden JA, Carroll M, Pirrie S, Bowden SJ, Dunachie SJ, Richter A, Lim Z, Satsangi J, Cook G, Pope A, Hughes A, Harrison M, Lim SH, Miller P, Klenerman P; PITCH consortium; Basu N, Gilmour A, Irwin S, Meacham G, Marjot T, Dimitriadis S, Kelleher P, Prendecki M, Clarke C, Mortimer P, McIntyre S, Selby R, Meardon N, Nguyen D, Tipton T, Longet S, Laidlaw S, Orchard K, Ireland G; CONSENSUS; Thomas D, Kearns P, Kirkham A, McInnes IB; OCTAVE Collaborative Group. Barnes E, et al. Nat Med. 2023 Jul;29(7):1760-1774. doi: 10.1038/s41591-023-02414-4. Epub 2023 Jul 6. Nat Med. 2023. PMID: 37414897 Free PMC article.

We report 474 SARS-CoV-2 infection episodes, including 48 individuals with hospitalization or death from COVID-19. Decreased magnitude of both the serological and the T cell response was associated with severe COVID-19. Overall, we identified clinical phenotypes tha …

We report 474 SARS-CoV-2 infection episodes, including 48 individuals with hospitalization or death from COVID-19. Decreased magnitud …

49

Evolving Horizons: Adenovirus Vectors' Timeless Influence on Cancer, Gene Therapy and Vaccines.

Trivedi PD, Byrne BJ, Corti M. Trivedi PD, et al. Viruses. 2023 Dec 3;15(12):2378. doi: 10.3390/v15122378. Viruses. 2023. PMID: 38140619 Free PMC article. Review.

Owing to the recent success of commercial oncolytic vector and multiple COVID-19 vaccines, adenovirus vectors are back in the spotlight. ...A significant emphasis is placed on their crucial role in advancing cancer therapy and the latest breakthroughs in vaccine …

Owing to the recent success of commercial oncolytic vector and multiple COVID-19 vaccines, adenovirus vectors are back in the spotlig …

50

BNT162b2 COVID-19 Vaccines in Children, Adolescents and Young Adults with Cancer-A 1-Year Follow-Up.

Donze C, Min V, Ninove L, de Lamballerie X, Revon Rivière G, Verschuur A, Saultier P, André N. Donze C, et al. Vaccines (Basel). 2023 May 16;11(5):989. doi: 10.3390/vaccines11050989. Vaccines (Basel). 2023. PMID: 37243093 Free PMC article.

(1) Background: Children and young adults with cancer are poorly represented in COVID-19 vaccination studies, and long-term protection conferred by vaccination is not known. (2) Objectives: 1. ...COVID-19 infections were mild, and vaccine seroconversio …

(1) Background: Children and young adults with cancer are poorly represented in COVID-19 vaccination studies, and long-term pr …

51

Determinants of influenza and COVID-19 vaccine intent or uptake in Lebanon: a scoping review of the literature.

Salam M, Honein-AbouHaidar G. Salam M, et al. BMC Infect Dis. 2023 Aug 6;23(1):511. doi: 10.1186/s12879-023-08478-4. BMC Infect Dis. 2023. PMID: 37544988 Free PMC article.

The search timeframe was up till December 31, 2022. Determinants of influenza and COVID-19 vaccine intent or uptake were categorized following the constructs of the Theory of Planned Behavior. ...Twenty one studies investigated COVID-19 vaccine intent …

The search timeframe was up till December 31, 2022. Determinants of influenza and COVID-19 vaccine intent or uptake were categ …

52

Modeling COVID-19 vaccine booster-elicited antibody response and impact of infection history.

Nishiyama T, Miyamatsu Y, Park H, Nakamura N, Yokokawa Shibata R, Iwami S, Nagasaki Y. Nishiyama T, et al. Vaccine. 2023 Dec 18;41(52):7655-7662. doi: 10.1016/j.vaccine.2023.11.040. Epub 2023 Nov 25. Vaccine. 2023. PMID: 38008663 Free article.

The 3-dose COVID-19 vaccine (booster vaccination) has been offered worldwide. ...

53

Immune responses and clinical outcomes after COVID-19 vaccination in patients with liver disease and liver transplant recipients.

Murray SM, Pose E, Wittner M, Londoño MC, Schaub G, Cook J, Dimitriadis S, Meacham G, Irwin S, Lim Z, Duengelhoef P, Sterneck M, Lohse AW, Perez V, Trivedi P, Bhandal K, Mullish BH, Manousou P, Provine NM, Avitabile E, Carroll M, Tipton T, Healy S, Burra P, Klenerman P, Dunachie S, Kronsteiner B, Maciola AK, Pasqual G, Hernandez-Gea V, Garcia-Pagan JC, Lampertico P, Iavarone M, Gines P, Lütgehetmann M, Schulze Zur Wiesch J, Russo FP, Barnes E, Marjot T; OCTAVE Collaborative Group, PITCH study, and the EASL supported COVID-Hep vaccine network. Murray SM, et al. J Hepatol. 2024 Jan;80(1):109-123. doi: 10.1016/j.jhep.2023.10.009. Epub 2023 Oct 19. J Hepatol. 2024. PMID: 37863203 Free PMC article.

SARS-CoV-2-specific T-cell and antibody responses were evaluated longitudinally after one to three vaccine doses, with long-term follow-up for COVID-19-related clinical outcomes. ...Overall, the three most widely available vaccine platforms were immunogenic a …

SARS-CoV-2-specific T-cell and antibody responses were evaluated longitudinally after one to three vaccine doses, with long-term foll …

54

Demographic Determinants and Geographical Variability of COVID-19 Vaccine Hesitancy in Underserved Communities: Cross-sectional Study.

Matas JL, Landry LG, Lee L, Hansel S, Coudray MS, Mata-McMurry LV, Chalasani N, Xu L, Stair T, Edwards C, Puckrein G, Meyer W, Wiltz G, Sampson M, Gregerson P, Barron C, Marable J, Akinboboye O, Il'yasova D. Matas JL, et al. JMIR Public Health Surveill. 2023 Apr 27;9:e34163. doi: 10.2196/34163. JMIR Public Health Surveill. 2023. PMID: 36811869 Free PMC article.

BACKGROUND: COVID-19 hospitalizations and deaths disproportionately affect underserved and minority populations, emphasizing that vaccine hesitancy can be an especially important public health risk factor in these populations. ...Vaccine hesitancy status was …

BACKGROUND: COVID-19 hospitalizations and deaths disproportionately affect underserved and minority populations, emphasizing that …

55

Lipid carriers for mRNA delivery.

Zhang W, Jiang Y, He Y, Boucetta H, Wu J, Chen Z, He W. Zhang W, et al. Acta Pharm Sin B. 2023 Oct;13(10):4105-4126. doi: 10.1016/j.apsb.2022.11.026. Epub 2022 Nov 30. Acta Pharm Sin B. 2023. PMID: 37799378 Free PMC article. Review.

Messenger RNA (mRNA) is the template for protein biosynthesis and is emerging as an essential active molecule to combat various diseases, including viral infection and cancer. Especially, mRNA-based vaccines, as a new type of vaccine, have played a leading role in f …

Messenger RNA (mRNA) is the template for protein biosynthesis and is emerging as an essential active molecule to combat various diseases, in …

56

Morphological and Metabolic Criteria of COVID-19 Vaccine Associated Axillary Nodes on 18-Fluorodeouxyglucose PET/CT Imaging in Breast Cancer Patients.

Fatima N, Zaman U, Zaman A, Zaman S, Tahseen R, Zaman MU. Fatima N, et al. Asian Pac J Cancer Prev. 2023 Dec 1;24(12):4053-4057. doi: 10.31557/APJCP.2023.24.12.4053. Asian Pac J Cancer Prev. 2023. PMID: 38156837 Free PMC article.

BACKGROUND: In the current era vaccine-associated lymphadenopathy (VAL) is not an uncommon presentation on 18F-FDG PET/CT examinations in patients inoculated with Coronavirus disease 2019 (COVID-19) vaccination. ...All patients had COVID-19 vaccine sho …

BACKGROUND: In the current era vaccine-associated lymphadenopathy (VAL) is not an uncommon presentation on 18F-FDG PET/CT examination …

57

Rational design of a booster vaccine against COVID-19 based on antigenic distance.

Hu YF, Yuen TT, Gong HR, Hu B, Hu JC, Lin XS, Rong L, Zhou CL, Chen LL, Wang X, Lei C, Yau T, Hung IF, To KK, Yuen KY, Zhang BZ, Chu H, Huang JD. Hu YF, et al. Cell Host Microbe. 2023 Aug 9;31(8):1301-1316.e8. doi: 10.1016/j.chom.2023.07.004. Epub 2023 Jul 31. Cell Host Microbe. 2023. PMID: 37527659 Free article.

To address this, we used antigenic distance to in silico select optimized booster vaccine seed strains effective against both current and future VOCs. Our model suggests that a SARS-CoV-1-based booster vaccine has the potential to cover a broader range of VOCs. Cand …

To address this, we used antigenic distance to in silico select optimized booster vaccine seed strains effective against both current …

58

Attitudes toward COVID-19 vaccine among pediatric patients with sickle cell disease and their caregivers.

Persaud Y, Mandrell BN, Sharma A, Carroll Y, Irvine M, Olufadi Y, Kang G, Hijano DR, Rai P, Hankins JS, Johnson LM. Persaud Y, et al. Pediatr Blood Cancer. 2023 May;70(5):e30274. doi: 10.1002/pbc.30274. Epub 2023 Mar 1. Pediatr Blood Cancer. 2023. PMID: 36860093

OBJECTIVE: To evaluate attitudes toward vaccination and vaccine uptake regarding coronavirus disease 2019 (COVID-19) among pediatric patients with sickle cell disease (SCD) and their caregivers. ...CONCLUSION: Despite the increased risk of severe illness due to C …

OBJECTIVE: To evaluate attitudes toward vaccination and vaccine uptake regarding coronavirus disease 2019 (COVID-19) among ped …

59

Safety of COVID-19 Vaccination in Patients With Breast Cancer: Cross-Sectional Study in China.

Zhang S, Li J, Xu R, Chen Q, Sun G, Lin Y, Cao Y, Chen Y, Geng C, Teng Y, Nie J, Li X, Xu G, Liu X, Jin F, Fan Z, Luo T, Liu H, Wang FS, Jiang Z. Zhang S, et al. JMIR Public Health Surveill. 2023 Dec 7;9:e46009. doi: 10.2196/46009. JMIR Public Health Surveill. 2023. PMID: 38060302 Free PMC article.

Patients with cancer are vulnerable to COVID-19 infection, adverse events, and high mortality, and should be the focus of epidemic prevention and treatment. ...Thus, it is safe for patients with breast cancer, especially for those in the early stage, to recei …

Patients with cancer are vulnerable to COVID-19 infection, adverse events, and high mortality, and should be the focus of epid …

60

COVID-19 and Influenza Vaccine Coadministration Among Older U.S. Adults.

Harris DA, Chachlani P, Hayes KN, McCarthy EP, Wen KJ, Deng Y, Zullo AR, Djibo DA, McMahill-Walraven CN, Smith-Ray RL, Gravenstein S, Mor V. Harris DA, et al. Am J Prev Med. 2024 Feb 23:S0749-3797(24)00067-9. doi: 10.1016/j.amepre.2024.02.013. Online ahead of print. Am J Prev Med. 2024. PMID: 38401746 Free article.

This study included community-dwelling Medicare beneficiaries 66 years who received an mRNA COVID-19 booster vaccine in Periods 1 and 2. The outcome was an influenza vaccine administered on the same day as the COVID-19 vaccine. ...RESULTS: Among …

This study included community-dwelling Medicare beneficiaries 66 years who received an mRNA COVID-19 booster vaccine in Period …

61

The impact of COVID-19 on cancer patients.

Wekking D, Senevirathne TH, Pearce JL, Aiello M, Scartozzi M, Lambertini M, De Silva P, Solinas C. Wekking D, et al. Cytokine Growth Factor Rev. 2024 Feb;75:110-118. doi: 10.1016/j.cytogfr.2023.11.004. Epub 2023 Nov 30. Cytokine Growth Factor Rev. 2024. PMID: 38103990 Review.

The COVID-19 pandemic poses a significant challenge for individuals with compromised immune systems, such as patients with cancer, as they face a heightened susceptibility to severe infections compared to the general population. ...Furthermore, it outlines risk fact …

The COVID-19 pandemic poses a significant challenge for individuals with compromised immune systems, such as patients with cancer …

62

Advances in mRNA-Based Cancer Vaccines.

Ni L. Ni L. Vaccines (Basel). 2023 Oct 16;11(10):1599. doi: 10.3390/vaccines11101599. Vaccines (Basel). 2023. PMID: 37897001 Free PMC article. Review.

Immunotherapy is a groundbreaking approach for treating cancer through harnessing the power of the immune system to target and eliminate cancer cells. ...However, with the maturity of mRNA technology and its success in tackling the recent coronavirus disease 2019 ( …

Immunotherapy is a groundbreaking approach for treating cancer through harnessing the power of the immune system to target and elimin …

63

Factors Associated with COVID-19 Vaccine Uptake Among Adolescents and Young Adults Recently Diagnosed with Cancer.

Kwok G, Reese S, Dugad S, Donovan KA, Tsui J, Sahler OJZ, Levonyan-Radloff K, Barnett ME, Manne S, Ohman-Strickland P, Devine KA. Kwok G, et al. J Adolesc Young Adult Oncol. 2024 Apr;13(2):352-357. doi: 10.1089/jayao.2022.0113. Epub 2022 Nov 11. J Adolesc Young Adult Oncol. 2024. PMID: 36367717

Adolescents and young adults (AYAs) recently diagnosed with cancer are medically vulnerable but little is known about vaccine uptake/intent in this group. AYAs reported on their COVID-19 vaccine uptake/intent. Logistic regression models examined factor …

Adolescents and young adults (AYAs) recently diagnosed with cancer are medically vulnerable but little is known about vaccine …

64

BioHabana 2022: Preventive and Immunotherapeutic Strategies Against COVID-19 and Cancer in Cuba.

Bello-Rivero I, Crombet-Ramos T, Mesa-Pardillo C, Morera-Díaz Y, Mazorra-Herrera Z, Garcia-Rivera D, Nodarse-Cuní H, Hernández-Bernal F, Muzio-Gonzalez V, Aguilera-Barreto A, Vazquez-Blomquist D, Domínguez-Horta MDC, Guillen-Nieto G. Bello-Rivero I, et al. J Interferon Cytokine Res. 2023 Dec;43(12):571-580. doi: 10.1089/jir.2023.0141. Epub 2023 Dec 4. J Interferon Cytokine Res. 2023. PMID: 38048299

The convergence of life sciences with neurosciences, nanotechnology, data management, and engineering has caused a technological diversification of the biotechnology, pharmaceutical, and medical technology industries, including the phenomenon of digital transformation, which has …

The convergence of life sciences with neurosciences, nanotechnology, data management, and engineering has caused a technological diversifica …

65

The Presence of Lung Cancer Affects SARS-CoV-2 Vaccine Uptake and Attitude in Chinese Patients: A Clinical Cross-Sectional Investigation.

Chen C, Pan R, Dai L, Chen M, Zhao J, Zhong W, Wang M, Liu H, Xu Y, Han X. Chen C, et al. Cancer Invest. 2023 Jul;41(6):601-616. doi: 10.1080/07357907.2023.2233624. Epub 2023 Jul 27. Cancer Invest. 2023. PMID: 37401814

With the SARS-CoV-2 mutations evolving and prompt of SARS-CoV-2 vaccines, no information is available on SARS-CoV-2 vaccination status in Chinese patients with lung cancer. An electronic questionnaire including sociodemographic characteristics, vaccine status, side …

With the SARS-CoV-2 mutations evolving and prompt of SARS-CoV-2 vaccines, no information is available on SARS-CoV-2 vaccination status in Ch …

66

Impact of COVID-19 pandemic and vaccine perceptions on HPV vaccine hesitancy.

Schelbar N, Ward CN, Phillips E, Herr MJ, Acevedo S, Conner H, Greiner A, Corriveau E. Schelbar N, et al. Am J Otolaryngol. 2024 Mar-Apr;45(2):104172. doi: 10.1016/j.amjoto.2023.104172. Epub 2023 Dec 13. Am J Otolaryngol. 2024. PMID: 38103489 Free article.

OBJECTIVE: This study evaluated the impact of the COVID-19 pandemic and vaccine perceptions on Human Papillomavirus (HPV) vaccine hesitancy. ...HPV vaccine series completion was significantly lower than COVID-19 vaccine series completion, …

OBJECTIVE: This study evaluated the impact of the COVID-19 pandemic and vaccine perceptions on Human Papillomavirus (HPV) v …

67

Racial differences in COVID-19 vaccine acceptance in Arkansas.

Amick Iii BC, Allen JL, Brown CC, Goudie A, Tilford M, Williams M. Amick Iii BC, et al. PLoS One. 2023 May 18;18(5):e0268876. doi: 10.1371/journal.pone.0268876. eCollection 2023. PLoS One. 2023. PMID: 37200371 Free PMC article.

The purpose of this study was to assess COVID-19 vaccine acceptance among adults living in a largely rural Southern state. ...The full COVID-19 vaccine acceptance scale was measured along with perceived vaccine safety, effectiveness, acceptance, …

The purpose of this study was to assess COVID-19 vaccine acceptance among adults living in a largely rural Southern state. ... …

68

Racial and Ethnic Variation in COVID-19 Vaccination Uptake Among Medicare Beneficiaries with Cancer History.

Poghosyan H, Dinan MA, Tamamyan G, Nelson L, Jeon S. Poghosyan H, et al. J Racial Ethn Health Disparities. 2023 Oct;10(5):2354-2362. doi: 10.1007/s40615-022-01415-2. Epub 2022 Sep 23. J Racial Ethn Health Disparities. 2023. PMID: 36149576 Free PMC article.

BACKGROUND: The purpose of this study was to estimate COVID-19 vaccination rate among Medicare beneficiaries with cancer history and determine whether COVID-19 vaccine uptake is higher among non-Hispanic White beneficiaries compared with racially and e …

BACKGROUND: The purpose of this study was to estimate COVID-19 vaccination rate among Medicare beneficiaries with cancer histo …

69

Axillary Lymph Nodes in Breast Cancer Patients After COVID-19 Vaccine.

Ozcan C, Dag A, Arslan B, Ozcan PP, Ustun RO, Turkegun M. Ozcan C, et al. Indian J Surg. 2023 May 13:1-6. doi: 10.1007/s12262-023-03804-1. Online ahead of print. Indian J Surg. 2023. PMID: 37361395 Free PMC article.

One of the side effects of vaccines used to end the COVID-19 epidemic is non-specifically enlarged axillary lymph nodes. ...This study has been designed to estimate the incidence of palpable enlarged axillary lymph node in breast cancer patients who had received …

One of the side effects of vaccines used to end the COVID-19 epidemic is non-specifically enlarged axillary lymph nodes. ...This stud …

70

Immunogenicity of COVID-19 vaccines in lung cancer patients.

Provencio M, Estival A, Franco F, López-Vivanco G, Saigí M, Arasanz H, Diz P, Carcereny E, García J, Aguado C, Mosquera J, Iruarrizaga E, Majem M, Bosch-Barrera J, Mielgo-Rubio X, Guirado M, Juan-Vidal Ó, Blasco A, Lucía Gozálvez C, Del Barrio A, De Portugal T, López-Martín A, Serrano G, Campos B, Rubio J, Catot S, Esteban B, Martí-Ciriquian JL, Del Barco E, Calvo V; Spanish Lung Cancer Group (SLGC/GECP). Provencio M, et al. Lung Cancer. 2023 Oct;184:107323. doi: 10.1016/j.lungcan.2023.107323. Epub 2023 Aug 9. Lung Cancer. 2023. PMID: 37639820 Free article.

OBJECTIVE: Patients with lung cancer are at increased risk of SARS-CoV-2 infection and severe complications from COVID-19, but information on the efficacy of anti-SARS-CoV-2 vaccine in these patients is scarce. We aimed at evaluating the safety and immunogeni …

OBJECTIVE: Patients with lung cancer are at increased risk of SARS-CoV-2 infection and severe complications from COVID-19, but …

71

Covid-19 vaccines elicit effective IgG responses in an elderly thymus cancer patient with chemotherapy.

Koller A, Szebeni J. Koller A, et al. Hum Vaccin Immunother. 2023 Dec 31;19(1):2188035. doi: 10.1080/21645515.2023.2188035. Epub 2023 Apr 16. Hum Vaccin Immunother. 2023. PMID: 37062957 Free PMC article.

A symptomless COVID-19 infection, however, greatly increased the serum level of anti-RBD IgG, which later subsided. This case confirms that an effective immune response can be achieved with a series of COVID-19 vaccinations despite cytostatic treatment in an old thy …

A symptomless COVID-19 infection, however, greatly increased the serum level of anti-RBD IgG, which later subsided. This case confirm …

72

The top 100 most cited articles on COVID-19 vaccine: a bibliometric analysis.

Wang W, Wang H, Yao T, Li Y, Yi L, Gao Y, Lian J, Feng Y, Wang S. Wang W, et al. Clin Exp Med. 2023 Oct;23(6):2287-2299. doi: 10.1007/s10238-023-01046-9. Epub 2023 Mar 20. Clin Exp Med. 2023. PMID: 36939968 Free PMC article. Clinical Trial.

The research on COVID-19 vaccine is currently the hottest topic in academic community. At present, COVID-19 vaccines researches have focused on vaccine efficacy, vaccine hesitancy, and the efficacy of current vaccines on omicron variants. ...

The research on COVID-19 vaccine is currently the hottest topic in academic community. At present, COVID-19 vaccines re …

73

The potential of mRNA vaccines in cancer nanomedicine and immunotherapy.

Pan S, Fan R, Han B, Tong A, Guo G. Pan S, et al. Trends Immunol. 2024 Jan;45(1):20-31. doi: 10.1016/j.it.2023.11.003. Epub 2023 Dec 22. Trends Immunol. 2024. PMID: 38142147 Review.

Owing to their outstanding performance against COVID-19, mRNA vaccines have brought great hope for combating various incurable diseases, including cancer. ...We also highlight the importance of delivery systems and chemical modifications for mRNA translation efficie …

Owing to their outstanding performance against COVID-19, mRNA vaccines have brought great hope for combating various incurable diseas …

74

Pediatric cancer care management during the COVID-19 pandemic: a review of the literature and a single-centre real-life experience of an Italian pediatric oncology unit.

Nigro O, Oltolini C, Barzaghi F, Uberti Foppa C, Cicalese MP, Massimino M, Schiavello E. Nigro O, et al. Expert Rev Anticancer Ther. 2023 Jul-Dec;23(9):927-942. doi: 10.1080/14737140.2023.2245148. Epub 2023 Sep 15. Expert Rev Anticancer Ther. 2023. PMID: 37712347 Review.

INTRODUCTION: The severe acute respiratory syndrome coronavirus-2 pandemic significantly affected clinical practice, also in pediatric oncology units. Cancer patients needed to be treated with an adequate dose density despite the SARS-CoV-2 infection, balancing risks of de …

INTRODUCTION: The severe acute respiratory syndrome coronavirus-2 pandemic significantly affected clinical practice, also in pediatric oncol …

75

Reduced SARS-CoV-2 mRNA vaccine immunogenicity and protection in mice with diet-induced obesity and insulin resistance.

O'Meara TR, Nanishi E, McGrath ME, Barman S, Dong D, Dillen C, Menon M, Seo HS, Dhe-Paganon S, Ernst RK, Levy O, Frieman MB, Dowling DJ. O'Meara TR, et al. J Allergy Clin Immunol. 2023 Nov;152(5):1107-1120.e6. doi: 10.1016/j.jaci.2023.06.031. Epub 2023 Aug 16. J Allergy Clin Immunol. 2023. PMID: 37595760 Free article.

OBJECTIVE: We sought to establish a connection between reduced immunization efficacy via modeling the effects of metabolic diseases on vaccine immunogenicity that is essential for the development of more effective vaccines for this distinct vulnerable population. ...Furthe …

OBJECTIVE: We sought to establish a connection between reduced immunization efficacy via modeling the effects of metabolic diseases on va …

76

The recovery strategies to support cervical cancer elimination in lower-and middle-income countries (LMICs) following COVID-19 disruptions.

Lee J, Ismail-Pratt I, Machalek DA, Kumarasamy S, Garland SM. Lee J, et al. Prev Med Rep. 2023 Jun 29;35:102291. doi: 10.1016/j.pmedr.2023.102291. eCollection 2023 Oct. Prev Med Rep. 2023. PMID: 37455756 Free PMC article. Review.

The COVID-19 pandemic has exacerbated the existing challenges to achieving the WHO target of eliminating cervical cancer as a public health problem by working towards the target of fewer than four cases per 100 000 women. ...In the aftermath of the COVID-19 p …

The COVID-19 pandemic has exacerbated the existing challenges to achieving the WHO target of eliminating cervical cancer as a …

77

Advanced nano-based strategies for mRNA tumor vaccine.

Qu Y, Xu J, Zhang T, Chen Q, Sun T, Jiang C. Qu Y, et al. Acta Pharm Sin B. 2024 Jan;14(1):170-189. doi: 10.1016/j.apsb.2023.07.025. Epub 2023 Jul 29. Acta Pharm Sin B. 2024. PMID: 38239240 Free PMC article. Review.

Tumor vaccine is a promising strategy for cancer immunotherapy by introducing tumor antigens into the body to activate specific anti-tumor immune responses. ...The latest progress in the nano-based strategies to overcome the bottleneck encountered in the delivery of …

Tumor vaccine is a promising strategy for cancer immunotherapy by introducing tumor antigens into the body to activate specifi …

78

COVID-19 Infection despite Previous Vaccination in Cancer Patients and Healthcare Workers: Results from a French Prospective Multicenter Cohort (PAPESCO-19).

Seegers V, Rousseau G, Zhou K, Blanc-Lapierre A, Bigot F, Mahammedi H, Lambert A, Moreau-Bachelard C, Campone M, Conroy T, Penault-Llorca F, Bellanger MM, Raoul JL. Seegers V, et al. Cancers (Basel). 2023 Sep 28;15(19):4777. doi: 10.3390/cancers15194777. Cancers (Basel). 2023. PMID: 37835471 Free PMC article.

In a multicenter prospective cohort of cancer patients (CP; n = 840) and healthcare workers (HCWs; n = 935) vaccinated against COVID-19, we noticed the following: i/after vaccination, 4.4% of HCWs and 5.8% of CP were infected; ii/no characteristic was associated wit …

In a multicenter prospective cohort of cancer patients (CP; n = 840) and healthcare workers (HCWs; n = 935) vaccinated against COV …

79

Factors associated with COVID-19 vaccine hesitancy among healthcare workers in Cameroon and Nigeria: a web-based cross-sectional study.

Aseneh JB, Agbor VN, Kadia BM, Okolie EA, Ofomata CJ, Etombi CL, Ekaney DSM, Joko Fru YW. Aseneh JB, et al. Int Health. 2023 Nov 3;15(6):702-714. doi: 10.1093/inthealth/ihad013. Int Health. 2023. PMID: 36905293 Free PMC article.

In addition, participants with chronic disease (aOR=0.34, 95% CI 0.12 to 0.97) and higher levels of concerns about getting COVID-19 (0.40, 0.18 to 0.87) were less likely to be hesitant to receive the COVID-19 vaccine. CONCLUSIONS: COVID-19 vaccine …

In addition, participants with chronic disease (aOR=0.34, 95% CI 0.12 to 0.97) and higher levels of concerns about getting COVID-19 ( …

80

COVID-19 Vaccination Messengers, Communication Channels, and Messages Trusted Among Black Communities in the USA: a Review.

Rabin Y, Kohler RE. Rabin Y, et al. J Racial Ethn Health Disparities. 2023 Nov 10. doi: 10.1007/s40615-023-01858-1. Online ahead of print. J Racial Ethn Health Disparities. 2023. PMID: 37947953 Review.

Black and African American adults exhibited higher levels of mistrust and vaccine hesitancy and lower levels of vaccination throughout the COVID-19 pandemic. ...Black communities wanted hopeful, fact-based messages that address racism and mistrust; persuasive messag …

Black and African American adults exhibited higher levels of mistrust and vaccine hesitancy and lower levels of vaccination throughou …

81

Effectiveness and safety of COVID-19 vaccination in people with blood cancer.

Copland E, Hirst J, Mi E, Patone M, Chen D, Coupland C, Hippisley-Cox J. Copland E, et al. Eur J Cancer. 2024 Apr;201:113603. doi: 10.1016/j.ejca.2024.113603. Epub 2024 Feb 5. Eur J Cancer. 2024. PMID: 38359496 Free article.

METHODS: Individuals aged 12 years as of 1st December 2020 in the QResearch primary care database were included. We assessed adjusted COVID-19 vaccine effectiveness (aVE) against COVID-19-related hospitalisation and death in people with blood cancer us …

METHODS: Individuals aged 12 years as of 1st December 2020 in the QResearch primary care database were included. We assessed adjusted COV …

82

Impact of methotrexate on humoral and cellular immune responses to SARS-CoV-2 mRNA vaccine in patients with rheumatoid arthritis.

Shirata M, Ito I, Tanaka M, Murata K, Murakami K, Ikeda H, Oi I, Hamao N, Nishioka K, Hayashi Y, Nagao M, Hashimoto M, Ito H, Ueno H, Morinobu A, Hirai T. Shirata M, et al. Clin Exp Med. 2023 Dec;23(8):4707-4720. doi: 10.1007/s10238-023-01163-5. Epub 2023 Aug 16. Clin Exp Med. 2023. PMID: 37582911

Humoral immune responses were assessed by quantifying anti-spike IgG antibody titers and the capacity of circulating antibodies to neutralize the ancestral SARS-CoV-2 strain and the Alpha, Delta, and Omicron variants. Vaccine-induced T-cell responses were measured using an …

Humoral immune responses were assessed by quantifying anti-spike IgG antibody titers and the capacity of circulating antibodies to neutraliz …

83

COVID-19 severity by vaccination status in the NCI COVID-19 and Cancer Patients Study (NCCAPS).

Best AF, Bowman M, Li J, Mishkin GE, Denicoff A, Shekfeh M, Rubinstein L, Warner JL, Rini B, Korde LA. Best AF, et al. J Natl Cancer Inst. 2023 May 8;115(5):597-600. doi: 10.1093/jnci/djad015. J Natl Cancer Inst. 2023. PMID: 36702472 Free PMC article.

We investigated the association of SARS CoV-2 vaccination with COVID-19 severity in a longitudinal study of adult cancer patients with COVID-19. ...We defined severe COVID-19 disease as hospitalization for COVID-19 or death within 30 days. ...

We investigated the association of SARS CoV-2 vaccination with COVID-19 severity in a longitudinal study of adult cancer patie …

84

COVID-19 in cancer patients: The impact of vaccination on outcomes early in the pandemic.

Khawaja F, Angelidakis G, Feldman A, Ravi V, Woodman E, Bhatti M, Ariza-Heredia E, Elhajj P, Spallone A, Jiang Y, Chemaly RF. Khawaja F, et al. Cancer Med. 2023 Dec;12(24):22006-22022. doi: 10.1002/cam4.6781. Epub 2023 Dec 8. Cancer Med. 2023. PMID: 38063366 Free PMC article.

We aimed to determine the protective effects of COVID-19 vaccination by comparing vaccinated and unvaccinated cancer patients after the initial phase of vaccine roll-out and to identify risk factors associated with hospitalization, severe COVID-19, and …

We aimed to determine the protective effects of COVID-19 vaccination by comparing vaccinated and unvaccinated cancer patients …

85

COVID-19 Vaccine Hesitancy Among People Living with HIV: A Systematic Review and Meta-Analysis.

Liu X, Wu Y, Huo Z, Zhang L, Jing S, Dai Z, Huang Y, Si M, Xin Y, Qu Y, Tang S, Su X. Liu X, et al. AIDS Behav. 2024 Apr 16. doi: 10.1007/s10461-024-04344-9. Online ahead of print. AIDS Behav. 2024. PMID: 38625625 Review.

During the COVID-19 pandemic, people living with HIV (PLWH) may have higher risks of infection, more serious complications, and worse prognosis without the protection of the COVID-19 vaccine. ...Although all PLWH are recommended to receive the COVID-19 …

During the COVID-19 pandemic, people living with HIV (PLWH) may have higher risks of infection, more serious complications, and worse …

86

Future prospects in mRNA vaccine development.

Mbatha LS, Akinyelu J, Maiyo F, Kudanga T. Mbatha LS, et al. Biomed Mater. 2023 Aug 17;18(5). doi: 10.1088/1748-605X/aceceb. Biomed Mater. 2023. PMID: 37589309 Review.

The recent advancements in messenger ribonucleic acid (mRNA) vaccine development have vastly enhanced their use as alternatives to conventional vaccines in the prevention of various infectious diseases and treatment of several types of cancers. ...This review gives a detai …

The recent advancements in messenger ribonucleic acid (mRNA) vaccine development have vastly enhanced their use as alternatives to co …

87

Structural and non-structural proteins in SARS-CoV-2: potential aspects to COVID-19 treatment or prevention of progression of related diseases.

Kakavandi S, Zare I, VaezJalali M, Dadashi M, Azarian M, Akbari A, Ramezani Farani M, Zalpoor H, Hajikhani B. Kakavandi S, et al. Cell Commun Signal. 2023 May 15;21(1):110. doi: 10.1186/s12964-023-01104-5. Cell Commun Signal. 2023. PMID: 37189112 Free PMC article. Review.

Coronavirus disease 2019 (COVID-19) is caused by a new member of the Coronaviridae family known as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). ...This review examines the potential role of these SARS-CoV-2 proteins in the initiation of chronic diseases, a …

Coronavirus disease 2019 (COVID-19) is caused by a new member of the Coronaviridae family known as severe acute respiratory syndrome …

88

Association of Regular Cervical Cancer Screening with Socioeconomic, COVID-19 Infection and Vaccine Status Among Japanese Population: Cohort Observational Study.

Mitoma T, Maki J, Ooba H, Ogawa C, Masuyama H, Tabuchi T. Mitoma T, et al. Int J Gen Med. 2024 Feb 13;17:541-551. doi: 10.2147/IJGM.S453675. eCollection 2024. Int J Gen Med. 2024. PMID: 38371520 Free PMC article.

PURPOSE: Among the Organisation for Economic Co-operation and Development countries, Japan has one of the lowest cervical cancer screening coverages. Cancer screening coverage has worsened due to the coronavirus disease of 2019 (COVID-19) pandemic. This study …

PURPOSE: Among the Organisation for Economic Co-operation and Development countries, Japan has one of the lowest cervical cancer scre …

89

Unlocking cancer vaccine potential: What are the key factors?

Grant M, Ni Lee L, Chinnakannan S, Tong O, Kwok J, Cianci N, Tillman L, Saha A, Pereira Almeida V, Leung C. Grant M, et al. Hum Vaccin Immunother. 2024 Dec 31;20(1):2331486. doi: 10.1080/21645515.2024.2331486. Epub 2024 Apr 2. Hum Vaccin Immunother. 2024. PMID: 38564321 Review.

Greater understanding of tumor biology, coupled with the success of vaccine technologies during the COVID-19 pandemic, has reinvigorated cancer vaccine development. ...Combining insights from previous cancer vaccine clinical development a …

Greater understanding of tumor biology, coupled with the success of vaccine technologies during the COVID-19 pandemic, has rei …

90

The implication of anti-PD-1 therapy in cancer patients for the vaccination against viral and other infectious diseases.

Retnakumar SV, Chauvin C, Bayry J. Retnakumar SV, et al. Pharmacol Ther. 2023 May;245:108399. doi: 10.1016/j.pharmthera.2023.108399. Epub 2023 Mar 30. Pharmacol Ther. 2023. PMID: 37001736 Review.

However, since cancer patients are not generally included in clinical trials for designing vaccines against infectious diseases, the possible interaction between vaccine immune responses and ICP therapy is largely unexplored. ...Therefore, while routine vaccination …

However, since cancer patients are not generally included in clinical trials for designing vaccines against infectious diseases, the …

91

Understanding Concerns about COVID-19 and Vaccination: Perspectives from Kidney Transplant Recipients.

MacEwan SR, Gaughan AA, Dixon GN, Olvera RG, Tarver WL, Rahurkar S, Rush LJ, Schenk AD, Stevens J, McAlearney AS. MacEwan SR, et al. Vaccines (Basel). 2023 Jun 22;11(7):1134. doi: 10.3390/vaccines11071134. Vaccines (Basel). 2023. PMID: 37514950 Free PMC article.

Vaccinated interviewees (n = 31) noted that they chose to receive a COVID-19 vaccine because of their increased risk due to their immunocompromised state. For unvaccinated interviewees (n = 7), reasons for not receiving a COVID-19 vaccine included conc …

Vaccinated interviewees (n = 31) noted that they chose to receive a COVID-19 vaccine because of their increased risk due to th …

92

Serological Response to SARS-CoV-2 after COVID-19 Vaccination in Lung Cancer Patients: Short Review.

Rodilla AM, Tavolacci S, Cagan J, Shah T, Mittan S, Mack PC, Hirsch FR. Rodilla AM, et al. Vaccines (Basel). 2023 May 11;11(5):969. doi: 10.3390/vaccines11050969. Vaccines (Basel). 2023. PMID: 37243073 Free PMC article. Review.

In comparison to the general population, lung cancer patients are more likely to suffer from severe Coronavirus disease (COVID-19) and associated mortality. Considering this increased risk, and in order to prevent symptoms and severe disease, patients with lung c …

In comparison to the general population, lung cancer patients are more likely to suffer from severe Coronavirus disease (COVID …

93

Coverage of primary and booster vaccination against COVID-19 by socioeconomic level: A nationwide cross-sectional registry study.

Hansen BT, Labberton AS, Kour P, Kraft KB. Hansen BT, et al. Hum Vaccin Immunother. 2023 Dec 31;19(1):2188857. doi: 10.1080/21645515.2023.2188857. Epub 2023 Mar 20. Hum Vaccin Immunother. 2023. PMID: 36941785 Free PMC article.

High and equitable COVID-19 vaccination coverage is important for pandemic control and prevention of health inequity. ...In conclusion, we document large socioeconomic inequalities in COVID-19 vaccination coverage, especially for booster vaccination, even though all …

High and equitable COVID-19 vaccination coverage is important for pandemic control and prevention of health inequity. ...In conclusio …

94

Association between social isolation and loneliness with COVID-19 vaccine uptake in Japan: a nationwide cross-sectional internet survey.

Ukai T, Tabuchi T. Ukai T, et al. BMJ Open. 2023 Nov 1;13(11):e073008. doi: 10.1136/bmjopen-2023-073008. BMJ Open. 2023. PMID: 37914296 Free PMC article.

OBJECTIVES: We examined the association between social isolation and loneliness, increasingly recognised but neglected social determinants of health, with being unvaccinated against COVID-19. DESIGN: This was a cross-sectional study. SETTING AND PARTICIPANTS: A representat …

OBJECTIVES: We examined the association between social isolation and loneliness, increasingly recognised but neglected social determinants o …

95

Adverse Effects Reported and Insights Following Sinopharm COVID-19 Vaccination.

Mohebbi A, Eterafi M, Fouladi N, Golizadeh M, Panahizadeh R, Habibzadeh S, Karimi K, Safarzadeh E. Mohebbi A, et al. Curr Microbiol. 2023 Oct 20;80(12):377. doi: 10.1007/s00284-023-03432-8. Curr Microbiol. 2023. PMID: 37861721

Vaccines are promising strategies for controlling COVID-19; however, COVID-19 vaccine side effects play a central role in public confidence in the vaccine and its uptake process. This study aimed to provide evidence on the post-vaccination early side e …

Vaccines are promising strategies for controlling COVID-19; however, COVID-19 vaccine side effects play a central role …

96

Fear of COVID-19 among cancer patients in Henan Province, Central China: causes, results, and coping factors.

Mao Y, Ma W, Kang D, Miao Y, Fu H, Zhang B, Zhang J, Wu J. Mao Y, et al. Front Psychol. 2023 Jun 16;14:1122894. doi: 10.3389/fpsyg.2023.1122894. eCollection 2023. Front Psychol. 2023. PMID: 37397338 Free PMC article.

OBJECTIVES: Cancer patients exhibit fear of COVID-19, which could lead to serious consequences. However, minimal information is available about the effect of the COVID-19 pandemic on the mental health of cancer patients. Therefore, this study aims to e …

OBJECTIVES: Cancer patients exhibit fear of COVID-19, which could lead to serious consequences. However, minimal information i …

97

Use of remdesivir for COVID-19 in patients with hematologic cancer.

Martin-Onraët A, Barrientos-Flores C, Vilar-Compte D, Pérez-Jimenez C, Alatorre-Fernandez P. Martin-Onraët A, et al. Clin Exp Med. 2023 Oct;23(6):2231-2238. doi: 10.1007/s10238-022-00964-4. Epub 2022 Dec 12. Clin Exp Med. 2023. PMID: 36508048 Free PMC article.

Fifty-two percent had non-Hodgkin lymphoma. Fifty patients (44%) had at least two doses of SARS-CoV-2 vaccine. COVID-19 was classified as mild (52.6%), moderate (9.7%), and severe/critical (28%). ...Nine patients received remdesivir at the ambulatory clinic (33%), t …

Fifty-two percent had non-Hodgkin lymphoma. Fifty patients (44%) had at least two doses of SARS-CoV-2 vaccine. COVID-19 was cl …

98

Progress in vaccine development for infectious diseases-a Keystone Symposia report.

Cable J, Graham BS, Koup RA, Seder RA, Karikó K, Pardi N, Barouch DH, Sharma B, Rauch S, Nachbagauer R, Forsell MNE, Schotsaert M, Ellebedy AH, Loré K, Irvine DJ, Pilkington E, Tahtinen S, Thompson EA, Feraoun Y, King NP, Saunders K, Alter G, Moin SM, Sliepen K, Karlsson Hedestam GB, Wardemann H, Pulendran B, Doria-Rose NA, He WT, Juno JA, Ataca S, Wheatley AK, McLellan JS, Walker LM, Lederhofer J, Lindesmith LC, Wille H, Hotez PJ, Bekker LG. Cable J, et al. Ann N Y Acad Sci. 2023 Jun;1524(1):65-86. doi: 10.1111/nyas.14975. Epub 2023 Apr 5. Ann N Y Acad Sci. 2023. PMID: 37020354

The COVID-19 pandemic has taught us many things, among the most important of which is that vaccines are one of the cornerstones of public health that help make modern longevity possible. ...On June 1-4, 2022, experts in vaccinology from academia, industry, and government c …

The COVID-19 pandemic has taught us many things, among the most important of which is that vaccines are one of the cornerstones of pu …

99

Attitudes towards HPV and COVID school-entry policies among adults living in Puerto Rico.

Rivera-Rivera JN, Díaz-Miranda OL, Medina-Laabes DT, Suárez E, Ortiz AP, Colón-López V. Rivera-Rivera JN, et al. Hum Vaccin Immunother. 2023 Dec 31;19(1):2202126. doi: 10.1080/21645515.2023.2202126. Epub 2023 Apr 24. Hum Vaccin Immunother. 2023. PMID: 37095591 Free PMC article.

Prior to the COVID pandemic, Puerto Rico (PR) had one of the highest Human Papillomavirus (HPV) vaccine rates in the United States. ...Further research should elucidate the implications of the COVID pandemic on HPV vaccine attitudes and adherence rates …

Prior to the COVID pandemic, Puerto Rico (PR) had one of the highest Human Papillomavirus (HPV) vaccine rates in the United St …

100

Comparative effectiveness of mRNA-1273 and BNT162b2 COVID-19 vaccines in immunocompromised individuals: a systematic review and meta-analysis using the GRADE framework.

Wang X, Haeussler K, Spellman A, Phillips LE, Ramiller A, Bausch-Jurken MT, Sharma P, Krivelyova A, Vats S, Van de Velde N. Wang X, et al. Front Immunol. 2023 Sep 12;14:1204831. doi: 10.3389/fimmu.2023.1204831. eCollection 2023. Front Immunol. 2023. PMID: 37771594 Free PMC article.

Influenza vaccine trials have shown that increasing dosage could improve effectiveness in IC populations. ...CONCLUSION: This GRADE meta-analysis based on a large number of consistent observational studies showed that the mRNA-1273 COVID-19 vaccine is associa …

Influenza vaccine trials have shown that increasing dosage could improve effectiveness in IC populations. ...CONCLUSION: This GRADE m …

101

Immunomodulators and risk for breakthrough infection after third COVID-19 mRNA vaccine among patients with rheumatoid arthritis: A cohort study.

Schiff AE, Wang X, Patel NJ, Kawano Y, Kowalski EN, Cook CE, Vanni KMM, Qian G, Bade KJ, Saavedra AA, Srivatsan S, Williams ZK, Venkat RK, Wallace ZS, Sparks JA. Schiff AE, et al. medRxiv [Preprint]. 2023 Oct 9:2023.10.08.23296717. doi: 10.1101/2023.10.08.23296717. medRxiv. 2023. PMID: 37873462 Free PMC article. Updated. Preprint.

Patients were followed from the date of 3rd vaccine dose until breakthrough COVID-19, death, or end of follow-up (18/Jan/2023). ...A sensitivity analysis excluding patients with cancer or interstitial lung disease yielded similar findings. CONCLUSIONS: We ide …

Patients were followed from the date of 3rd vaccine dose until breakthrough COVID-19, death, or end of follow-up (18/Jan/2023) …

102

Novel Psychosocial Correlates of COVID-19 Vaccine Hesitancy: Cross-Sectional Survey.

Bacon E, An L, Yang P, Hawley S, Van Horn ML, Resnicow K. Bacon E, et al. JMIR Form Res. 2023 Sep 27;7:e45980. doi: 10.2196/45980. JMIR Form Res. 2023. PMID: 37756115 Free PMC article.

As of mid-2022, still around 30% of US adults remain unvaccinated against COVID-19. The majority (81%) of these unvaccinated adults say they will "definitely not" be getting the COVID-19 vaccine. Understanding the determinants of COVID-19 vaccine …

As of mid-2022, still around 30% of US adults remain unvaccinated against COVID-19. The majority (81%) of these unvaccinated adults s …

103

COVID-19 vaccine immune response in patients with plasma cell dyscrasia: a systematic review.

Faizan U, Nair LG, Bou Zerdan M, Jaberi-Douraki M, Anwer F, Raza S. Faizan U, et al. Ther Adv Vaccines Immunother. 2023 Aug 27;11:25151355231190497. doi: 10.1177/25151355231190497. eCollection 2023. Ther Adv Vaccines Immunother. 2023. PMID: 37645011 Free PMC article. Review.

BACKGROUND: Patients with plasma cell dyscrasia are at a higher risk of developing a severe Coronavirus-2019 (COVID-19) infection. Here we present a systematic review of clinical studies focusing on the immune response to the COVID-19 vaccination in patients with pl …

BACKGROUND: Patients with plasma cell dyscrasia are at a higher risk of developing a severe Coronavirus-2019 (COVID-19) infection. He …

104

"When you get the HPV vaccine, it will prevent cervical cancer; it will act as a shield": adolescent girls' knowledge and perceptions regarding the human papillomavirus vaccine in Zambia.

Lubeya MK, Chibwesha CJ, Mwanahamuntu M, Mukosha M, Frank S, Kawonga M. Lubeya MK, et al. Front Health Serv. 2023 Sep 13;3:1208458. doi: 10.3389/frhs.2023.1208458. eCollection 2023. Front Health Serv. 2023. PMID: 37780403 Free PMC article.

However, the adolescents' knowledge and perceptions regarding the HPV vaccine are not well understood. Therefore, this study aimed to understand adolescent girls' knowledge and perceptions regarding the HPV vaccine and discuss its acceptability and uptake implicatio …

However, the adolescents' knowledge and perceptions regarding the HPV vaccine are not well understood. Therefore, this study aimed to …

105

COVID-19 vaccine hesitancy in community-dwelling and hospitalized patients with severe mental illness.

Bai W, Cai H, Jin Y, Zhang Q, Cheung T, Su Z, Tang YL, Ng CH, Xiang YT. Bai W, et al. Psychol Med. 2023 Jul;53(9):4288-4290. doi: 10.1017/S0033291721004918. Epub 2021 Dec 17. Psychol Med. 2023. PMID: 34915962 Free PMC article. No abstract available.

106

Response to COVID-19 Vaccination Post-CAR T Therapy in Patients With Non-Hodgkin Lymphoma and Multiple Myeloma.

Wiedmeier-Nutor JE, Iqbal M, Rosenthal AC, Bezerra ED, Garcia-Robledo JE, Bansal R, Johnston PB, Hathcock M, Larsen JT, Bergsagel PL, Wang Y, Reeder CB, Leis JF, Fonseca R, Palmer JM, Gysbers BJ, Mwangi R, Warsame RM, Kourelis T, Hayman SR, Dingli D, Kapoor P, Kumar SK, Durani U, Villasboas JC, Paludo J, Bennani NN, Nowakowski G, Ansell SM, Castro JE, Kharfan-Dabaja MA, Lin Y, Vergidis P, Murthy HS, Munoz J. Wiedmeier-Nutor JE, et al. Clin Lymphoma Myeloma Leuk. 2023 Jun;23(6):456-462. doi: 10.1016/j.clml.2023.03.002. Epub 2023 Mar 7. Clin Lymphoma Myeloma Leuk. 2023. PMID: 37003846 Free PMC article.

COVID-19 adversely affects individuals with cancer. Several studies have found that seroconversion rates among patients with hematologic malignancies are suboptimal when compared to patients without cancer. ...Out of 104 CAR T infusions, 19 patients developed …

COVID-19 adversely affects individuals with cancer. Several studies have found that seroconversion rates among patients with h …

107

PD-1/PD-L1 blockade restores tumor-induced COVID-19 vaccine bluntness.

Chen X, Lin Y, Yue S, Yang Y, Yang X, He J, Gao L, Li Z, Hu L, Tang J, Wang Y, Tian Q, Hao Y, Xu L, Huang Q, Cao Y, Ye L. Chen X, et al. Vaccine. 2023 Jul 31;41(34):4986-4995. doi: 10.1016/j.vaccine.2023.06.053. Epub 2023 Jun 20. Vaccine. 2023. PMID: 37400286 Free PMC article.

However, accumulating studies revealed the severely blunted COVID-19 vaccine effectiveness in cancer patients. The PD-1/PD-L1 immune checkpoint blockade (ICB) therapy leads to durable therapeutic responses in a subset of cancer patients and has been ap …

However, accumulating studies revealed the severely blunted COVID-19 vaccine effectiveness in cancer patients. The PD-1 …

108

Socio-economic disparities in exposure to and endorsement of COVID-19 vaccine misinformation and the associations with vaccine hesitancy and vaccination.

Yao Y, Wu YS, Weng X, Viswanath K, Lee EWJ, Wang MP. Yao Y, et al. Public Health. 2023 Oct;223:217-222. doi: 10.1016/j.puhe.2023.08.005. Epub 2023 Sep 8. Public Health. 2023. PMID: 37677851

OBJECTIVES: We examined disparities in vaccine misinformation exposure and endorsement and the associations with vaccine hesitancy and vaccination uptake. ...CONCLUSION: Endorsement of vaccine misinformation in respondents with lower SES was associated with l …

OBJECTIVES: We examined disparities in vaccine misinformation exposure and endorsement and the associations with vaccine hesit …

109

COVID-19 vaccine equity and health equity conversations on Twitter.

Jain NR, Zachary I, Boren SA. Jain NR, et al. AMIA Annu Symp Proc. 2024 Jan 11;2023:997-1006. eCollection 2023. AMIA Annu Symp Proc. 2024. PMID: 38222403 Free PMC article.

This study used social network analysis and trending hashtags on Twitter to identify trends related to health and vaccine equity during the Omicron wave. The analysis was conducted using consumer-friendly platforms/tools such as the Healthcare Hashtag Project and NodeXL. . …

This study used social network analysis and trending hashtags on Twitter to identify trends related to health and vaccine equity duri …

110

Nelli F, Giannarelli D, Fabbri A, Virtuoso A, Giron Berrios JR, Marrucci E, Fiore C, Schirripa M, Signorelli C, Chilelli MG, Primi F, Panichi V, Topini G, Silvestri MA, Ruggeri EM. Nelli F, et al. Cancer Immunol Immunother. 2023 Oct;72(10):3217-3228. doi: 10.1007/s00262-023-03489-1. Epub 2023 Jul 10. Cancer Immunol Immunother. 2023. PMID: 37428196

BACKGROUND: The clinical implications of the third dose of coronavirus disease 2019 (COVID-19) vaccines in patients receiving immune checkpoint inhibitors are currently unknown. ...METHODS: Recipients of the booster dose of SARS-CoV-2 mRNA-BNT162b2 vaccine who had r …

BACKGROUND: The clinical implications of the third dose of coronavirus disease 2019 (COVID-19) vaccines in patients receiving immune …

111

Maternal COVID-19 Vaccination and Prevention of Symptomatic Infection in Infants.

Cardemil CV, Cao Y, Posavad CM, Badell ML, Bunge K, Mulligan MJ, Parameswaran L, Olson-Chen C, Novak RM, Brady RC, DeFranco E, Gerber JS, Pasetti M, Shriver M, Coler R, Berube B, Suthar MS, Moreno A, Gao F, Richardson BA, Beigi R, Brown E, Neuzil KM, Munoz FM; MOMI-Vax Study Group. Cardemil CV, et al. Pediatrics. 2024 Mar 1;153(3):e2023064252. doi: 10.1542/peds.2023-064252. Pediatrics. 2024. PMID: 38332733

BACKGROUND AND OBJECTIVES: Maternal vaccination may prevent infant coronavirus disease 2019 (COVID-19). We aimed to quantify protection against infection from maternally derived vaccine-induced antibodies in the first 6 months of an infant's life. METHODS: Infants b …

BACKGROUND AND OBJECTIVES: Maternal vaccination may prevent infant coronavirus disease 2019 (COVID-19). We aimed to quantify protecti …

112

Immune responses and disease biomarker long-term changes following COVID-19 mRNA vaccination in a cohort of rheumatic disease patients.

An Z, Figueroa-Parra G, Zhou X, Li Y, Jaquith J, McCarthy-Fruin K, Sletten J, Warrington KJ, Weyand C, Crowson CS, Chumsri S, Knutson KL, Sanchez-Rodriguez A, Thanarajasingam U, Duarte-García A, Zeng H. An Z, et al. Front Immunol. 2023 Jul 31;14:1224702. doi: 10.3389/fimmu.2023.1224702. eCollection 2023. Front Immunol. 2023. PMID: 37583697 Free PMC article.

INTRODUCTION: The longitudinal responses towards multiple doses of COVID-19 mRNA vaccines in patients with systemic autoimmune diseases remain incompletely understood. While observational studies suggested the safety of COVID-19 mRNA vaccines in rheumatic disease pa …

INTRODUCTION: The longitudinal responses towards multiple doses of COVID-19 mRNA vaccines in patients with systemic autoimmune diseas …

113

Effectiveness of various COVID-19 vaccine regimens among 10.4 million patients from the National COVID Cohort Collaborative during Pre-Delta to Omicron periods - United States, 11 December 2020 to 30 June 2022.

Fu Y, Wu K, Wang Z, Yang H, Chen Y, Wu L, Yanagihara R, Hedges JR, Wang H, Deng Y; N3C consortium. Fu Y, et al. Vaccine. 2023 Oct 6;41(42):6339-6349. doi: 10.1016/j.vaccine.2023.08.069. Epub 2023 Sep 22. Vaccine. 2023. PMID: 37741761

OBJECTIVE: This study reports the vaccine effectiveness (VE) of COVID-19 vaccine regimens in the United States, based on the National COVID Cohort Collaborative (N3C) database. ...VE against infection and death outcomes were evaluated across 13 vacc …

OBJECTIVE: This study reports the vaccine effectiveness (VE) of COVID-19 vaccine regimens in the United States, based o …

114

Survival and safety analysis of COVID-19 vaccine in Chinese patients with non-small cell lung cancer.

Xu W, Zhao J, Luan F, Zhang Z, Liu L, Zhao H, Feng B, Fu G. Xu W, et al. Cancer Med. 2024 Apr;13(8):e7032. doi: 10.1002/cam4.7032. Cancer Med. 2024. PMID: 38651178

We aimed to assess the safety and efficacy of the COVID-19 vaccines in Non-Small Cell Lung Cancer (NSCLC) patients. ...The vaccination rate was 71.11% for early-stage patients and 19.48% for advanced-stage patients; most of them (86.5%) received the COVID-19 …

We aimed to assess the safety and efficacy of the COVID-19 vaccines in Non-Small Cell Lung Cancer (NSCLC) patients. ...The vac …

115

Effectiveness of COVID-19 vaccination against COVID-19 specific and all-cause mortality in older Australians: a population based study.

Liu B, Stepien S, Dobbins T, Gidding H, Henry D, Korda R, Mills L, Pearson SA, Pratt N, Vajdic CM, Welsh J, Macartney K. Liu B, et al. Lancet Reg Health West Pac. 2023 Oct 7;40:100928. doi: 10.1016/j.lanwpc.2023.100928. eCollection 2023 Nov. Lancet Reg Health West Pac. 2023. PMID: 37854458 Free PMC article.

During January-May, VE of a 3rd COVID-19 vaccine dose within 3 months was 93% (95% CI 93-94%) whilst VE of a 2nd dose >6 months since receipt was 34% (26-42%). During June-November, VE of a 4th COVID-19 vaccine dose within 3 months was 84% (82-86%) …

During January-May, VE of a 3rd COVID-19 vaccine dose within 3 months was 93% (95% CI 93-94%) whilst VE of a 2nd dose >6 mo …

116

Relationship between COVID-19 vaccine hesitancy and willingness to pay for the booster dose of COVID-19 vaccine of oncology patients in Taizhou, China.

An JX, Lin XQ, Xie BJ, Tung TH, Zhu JS. An JX, et al. Ann Med. 2023 Dec;55(1):672-679. doi: 10.1080/07853890.2023.2165705. Ann Med. 2023. PMID: 36840655 Free PMC article.

OBJECTIVE: This population-based study aimed to determine the hesitancy and willingness to pay (WTP) for the booster dose of a coronavirus disease (COVID-19) vaccine among patients with cancer in Taizhou, China. PATIENTS AND METHODS: A self-administered onlin …

OBJECTIVE: This population-based study aimed to determine the hesitancy and willingness to pay (WTP) for the booster dose of a coronavirus d …

117

Behavioral and Social Drivers of COVID-19 Vaccination in the United States, August-November 2021.

Bonner KE, Vashist K, Abad NS, Kriss JL, Meng L, Lee JT, Wilhelm E, Lu PJ, Carter RJ, Boone K, Baack B, Masters NB, Weiss D, Black C, Huang Q, Vangala S, Albertin C, Szilagyi PG, Brewer NT, Singleton JA. Bonner KE, et al. Am J Prev Med. 2023 Jun;64(6):865-876. doi: 10.1016/j.amepre.2023.01.014. Epub 2023 Jan 25. Am J Prev Med. 2023. PMID: 36775756 Free PMC article.

RESULTS: Among the 255,763 respondents, 76% received their first dose of COVID-19 vaccine. Vaccine uptake was higher among respondents aged 75 years (94%), females (78%), and Asian non-Hispanic people (94%). ...Interventions that leverage these social and beh …

RESULTS: Among the 255,763 respondents, 76% received their first dose of COVID-19 vaccine. Vaccine uptake was higher am …

118

Cytokine-responsive T- and NK-cells portray SARS-CoV-2 vaccine-responders and infection in multiple myeloma patients.

Enssle JC, Campe J, Moter A, Voit I, Gessner A, Yu W, Wolf S, Steffen B, Serve H, Bremm M, Huenecke S, Lohoff M, Vehreschild M, Rabenau HF, Widera M, Ciesek S, Oellerich T, Imkeller K, Rieger MA, von Metzler I, Ullrich E. Enssle JC, et al. Leukemia. 2024 Jan;38(1):168-180. doi: 10.1038/s41375-023-02070-0. Epub 2023 Dec 4. Leukemia. 2024. PMID: 38049509 Free PMC article.

Patients with multiple myeloma (MM) routinely receive mRNA-based vaccines to reduce COVID-19-related mortality. However, whether disease- and therapy-related alterations in immune cells and cytokine-responsiveness contribute to the observed heterogeneous vaccination respon …

Patients with multiple myeloma (MM) routinely receive mRNA-based vaccines to reduce COVID-19-related mortality. However, whether dise …

119

Knowledge, attitudes, and practices (KAP) toward seasonal influenza vaccine among college students under the COVID-19 pandemic in South China.

Wu D, Mai Y, Liu P, Long J, Liu Q, Wu T, Wang D, Hu X, Lin W, Chen X, Zhang Z, Qin P. Wu D, et al. Immun Inflamm Dis. 2023 Dec;11(12):e1110. doi: 10.1002/iid3.1110. Immun Inflamm Dis. 2023. PMID: 38156389 Free PMC article.

BACKGROUND: The control measures of the coronavirus disease 2019 (COVID-19) pandemic had influenced the activity of the influenza virus, and we were wondering the knowledge, attitudes, and practices (KAP) toward seasonal influenza vaccine among college students were …

BACKGROUND: The control measures of the coronavirus disease 2019 (COVID-19) pandemic had influenced the activity of the influenza vir …

120

It's Time for a National Surveillance System for Vaccine Confidence and Hesitancy.

Gilkey MB, Brewer NT. Gilkey MB, et al. Pediatrics. 2023 Nov 1;152(5):e2023063169. doi: 10.1542/peds.2023-063169. Pediatrics. 2023. PMID: 37867453 No abstract available.

121

Forster M, Wuerstlein R, Koenig A, Stefan A, Wiegershausen E, Batz F, Trillsch F, Mahner S, Harbeck N, Chelariu-Raicu A. Forster M, et al. Front Oncol. 2023 Oct 12;13:1217805. doi: 10.3389/fonc.2023.1217805. eCollection 2023. Front Oncol. 2023. PMID: 37901314 Free PMC article.

Patients with breast cancer (n= 83) had early (59.0%) or metastatic cancer (41.0%); gynecological cancers (n=31) also included metastatic (54.8%) and non-metastatic cancer (45.2%). 83.3% of the patients stated that COVID-19 vaccination had a positive i …

Patients with breast cancer (n= 83) had early (59.0%) or metastatic cancer (41.0%); gynecological cancers (n=31) also included …

122

Medical Mistrust, Perceived Discrimination, and Race: a Longitudinal Analysis of Predictors of COVID-19 Vaccine Hesitancy in US Adults.

Morgan KM, Maglalang DD, Monnig MA, Ahluwalia JS, Avila JC, Sokolovsky AW. Morgan KM, et al. J Racial Ethn Health Disparities. 2023 Aug;10(4):1846-1855. doi: 10.1007/s40615-022-01368-6. Epub 2022 Aug 1. J Racial Ethn Health Disparities. 2023. PMID: 35913543 Free PMC article.

First, we examined whether race and ethnicity, perceived discrimination, medical mistrust, and other demographic factors were predictors of COVID-19 vaccine hesitancy and vaccine behavior. Second, we sought to assess whether medical mistrust and perceived dis …

First, we examined whether race and ethnicity, perceived discrimination, medical mistrust, and other demographic factors were predictors of …

123

Comparative Assessment of the Kinetics of Cellular and Humoral Immune Responses to COVID-19 Vaccination in Cancer Patients.

Souan L, Abdel-Razeq H, Al Zughbieh M, Al Badr S, Sughayer MA. Souan L, et al. Viruses. 2023 Jun 26;15(7):1439. doi: 10.3390/v15071439. Viruses. 2023. PMID: 37515127 Free PMC article.

COVID-19 immunizations helped cancer patients develop an effective immune response. Understanding the cellular and humoral immune response to COVID-19 in cancer patients undergoing active treatment is necessary to improve vaccines and avoid future SARS …

COVID-19 immunizations helped cancer patients develop an effective immune response. Understanding the cellular and humoral imm …

124

A Three-Dose mRNA COVID-19 Vaccine Regime Produces Both Suitable Immunogenicity and Satisfactory Efficacy in Patients with Solid Cancers.

Janzic U, Bidovec-Stojkovic U, Korosec P, Mohorcic K, Mrak L, Caks M, Ravnik M, Skof E, Rijavec M. Janzic U, et al. Vaccines (Basel). 2023 May 23;11(6):1017. doi: 10.3390/vaccines11061017. Vaccines (Basel). 2023. PMID: 37376406 Free PMC article.

BACKGROUND: The recommended booster third dose of vaccination against COVID-19 in cancer patients seems reasonable to protect them against a severe disease course. ...No patients had either a severe disease course or a lethal outcome in the case of SARS-CoV-2 infect …

BACKGROUND: The recommended booster third dose of vaccination against COVID-19 in cancer patients seems reasonable to protect …

125

Mycobacterium Indicus Pranii (MIP) Vaccine: Pharmacology, Indication, Dosing Schedules, Administration, and Side Effects in Clinical Practice.

Dogra S, Jain S, Sharma A, Chhabra S, Narang T. Dogra S, et al. Indian Dermatol Online J. 2023 Oct 17;14(6):753-761. doi: 10.4103/idoj.idoj_360_23. eCollection 2023 Nov-Dec. Indian Dermatol Online J. 2023. PMID: 38099011 Free PMC article. Review.

Mycobacterium indicus pranii (MIP), previously called Mw vaccine, is a one-of-a-kind immunomodulatory vaccine. It was indigenously developed in India for use in leprosy. ...Clinical trials have evaluated the efficacy of MIP in a plenitude of non-dermatological condi …

Mycobacterium indicus pranii (MIP), previously called Mw vaccine, is a one-of-a-kind immunomodulatory vaccine. It was indigeno …

126

Safety and Immunogenicity of Homologous and Heterologous Adenoviral-Vectored and mRNA COVID-19 Vaccine Regimens in Radiotherapy Patients.

Prayongrat A, Noppaving P, Chobarporn T, Sudhinaraset N, Teeyapun N, Pakvisal N, Jantarabenjakul W, Sophonphan J, Lertbutsayanukul C, Poovorawan Y. Prayongrat A, et al. Vaccines (Basel). 2023 Jun 23;11(7):1135. doi: 10.3390/vaccines11071135. Vaccines (Basel). 2023. PMID: 37514951 Free PMC article.

Diminished immune response after vaccination occurs in cancer patients. This observational study evaluated the immune response and safety profile after COVID-19 vaccination in radiotherapy patients. The study comprised 53 cancer patients undergoing radiothera …

Diminished immune response after vaccination occurs in cancer patients. This observational study evaluated the immune response and sa …

127

Factors associated with COVID-19 booster vaccine hesitancy: a nationwide, cross-sectional survey in Japan.

Takamatsu A, Honda H, Miwa T, Tabuchi T, Taniguchi K, Shibuya K, Tokuda Y. Takamatsu A, et al. Public Health. 2023 Oct;223:72-79. doi: 10.1016/j.puhe.2023.07.022. Epub 2023 Aug 22. Public Health. 2023. PMID: 37619504

The public's perceptions of COVID-19 vaccination and factors associated with COVID-19 booster vaccine hesitancy were analyzed. ...Factors independently associated with booster vaccine hesitancy were young age (range: 18-29 years; adjusted odds ratio [a …

The public's perceptions of COVID-19 vaccination and factors associated with COVID-19 booster vaccine hesitancy were an …

128

Cost-based COVID-19 vaccination and willingness to pay: A post-pandemic review.

Wong LP, Lee HY, Alias H, Zimet G, Liu T, Lin Y, Hu Z. Wong LP, et al. Hum Vaccin Immunother. 2024 Dec 31;20(1):2313860. doi: 10.1080/21645515.2024.2313860. Epub 2024 Feb 15. Hum Vaccin Immunother. 2024. PMID: 38359815 Free PMC article. Review.

The potential consequences of shifting from free to cost-based vaccination are explored, encompassing its impact on global vaccine equity and prioritization, economic well-being, healthcare systems and delivery, public health policies, and vaccine distribution strat …

The potential consequences of shifting from free to cost-based vaccination are explored, encompassing its impact on global vaccine eq …

129

Letter to the Editor: COVID-19 Vaccine Uptake Among Adolescents and Young Adults Diagnosed with Cancer: Correspondence.

Mungmunpuntipantip R, Wiwanitkit V. Mungmunpuntipantip R, et al. J Adolesc Young Adult Oncol. 2023 Oct;12(5):794. doi: 10.1089/jayao.2022.0161. Epub 2022 Dec 14. J Adolesc Young Adult Oncol. 2023. PMID: 36520612 No abstract available.

130

Cationic crosslinked carbon dots-adjuvanted intranasal vaccine induces protective immunity against Omicron-included SARS-CoV-2 variants.

Lei H, Alu A, Yang J, He X, He C, Ren W, Chen Z, Hong W, Chen L, He X, Yang L, Li J, Wang Z, Wang W, Wei Y, Lu S, Lu G, Song X, Wei X. Lei H, et al. Nat Commun. 2023 May 9;14(1):2678. doi: 10.1038/s41467-023-38066-8. Nat Commun. 2023. PMID: 37160882 Free PMC article.

However, the lack of effective and safe adjuvants currently limits the development of COVID-19 mucosal vaccines. In the current study, we prepare an intranasal vaccine containing cationic crosslinked carbon dots (CCD) and a SARS-CoV-2 antigen, RBD-HR with spontaneou …

However, the lack of effective and safe adjuvants currently limits the development of COVID-19 mucosal vaccines. In the current study …

131

The Disease Influenced Vaccine Acceptance Scale-Six (DIVAS-6): Validation of a Measure to Assess Disease-Related COVID-19 Vaccine Attitudes and Concerns.

Grech L, Loe BS, Day D, Freeman D, Kwok A, Nguyen M, Bain N, Segelov E. Grech L, et al. Behav Med. 2023 Oct-Dec;49(4):402-411. doi: 10.1080/08964289.2022.2082358. Epub 2022 Jun 15. Behav Med. 2023. PMID: 35703037

We developed a six-item scale assessing disease-related COVID-19 vaccine attitudes and concerns (The Disease Influenced COVID-19 Vaccine Acceptance Scale-Six: DIVAS-6). ...This is the first validated scale to measure disease-related COVID-19 …

We developed a six-item scale assessing disease-related COVID-19 vaccine attitudes and concerns (The Disease Influenced COV …

132

Covid19Vaxplorer: a free, online, user-friendly COVID-19 Vaccine Allocation Comparison Tool.

Trejo I, Hung PY, Matrajt L. Trejo I, et al. medRxiv [Preprint]. 2023 Nov 11:2023.06.15.23291472. doi: 10.1101/2023.06.15.23291472. medRxiv. 2023. PMID: 37986918 Free PMC article. Updated. Preprint.

METHODS: We developed an age-structured mathematical model of SARS-CoV-2 transmission and COVID-19 vaccination. The model considers vaccination with up to three different vaccine products, primary series and boosters. ...By prompting users to fill information throug …

METHODS: We developed an age-structured mathematical model of SARS-CoV-2 transmission and COVID-19 vaccination. The model considers v …

133

Fear, Anxiety, and Coping Self-efficacy of Individuals With Cancer During COVID-19 and Predictive Risk Factors: A Descriptive and Correlational Study.

Karataş T, Ayaz-Alkaya S, Özdemir N. Karataş T, et al. Semin Oncol Nurs. 2023 Aug;39(4):151420. doi: 10.1016/j.soncn.2023.151420. Epub 2023 Mar 14. Semin Oncol Nurs. 2023. PMID: 37037701 Free PMC article.

OBJECTIVES: In this study, we determined COVID-19-related fear, anxiety, and coping self-efficacy in individuals with cancer and predicted the risk factors of these parameters. ...Approximately 94% of individuals had received the COVID-19 vaccine. The …

OBJECTIVES: In this study, we determined COVID-19-related fear, anxiety, and coping self-efficacy in individuals with cancer a …

134

Safety and efficacy of dendritic cell vaccine for COVID-19 prevention after 1-Year follow-up: phase I and II clinical trial final result.

Jonny J, Putranto TA, Yana ML, Sitepu EC, Irfon R, Ramadhani BP, Sofro MAU, Nency YM, Lestari ES, Triwardhani R, Mujahidah, Sari RK, Soetojo NA. Jonny J, et al. Front Immunol. 2023 Jun 19;14:1122389. doi: 10.3389/fimmu.2023.1122389. eCollection 2023. Front Immunol. 2023. PMID: 37404828 Free PMC article. Clinical Trial.

Meanwhile, 4.31% of subjects in phase II had moderate-severe COVID-19. There is no difference in both COVID and non-COVID-19 AEs between groups. CONCLUSIONS: After 1 year of follow-up, this vaccine is proven safe and effective for preventing COVID …

Meanwhile, 4.31% of subjects in phase II had moderate-severe COVID-19. There is no difference in both COVID and non-COVID …

135

COVID-19 vaccine hesitancy: assessing the prevalence, predictors, and effectiveness of a community pharmacy based counseling intervention.

Kiptoo J, Isiiko J, Yadesa TM, Rhodah T, Alele PE, Mulogo EM. Kiptoo J, et al. BMC Public Health. 2024 Jan 6;24(1):111. doi: 10.1186/s12889-023-17532-4. BMC Public Health. 2024. PMID: 38184570 Free PMC article.

RESULTS: Out of 394 participants, 221 (56%) were hesitant to receive a COVID-19 vaccine. Participants expressed several reasons (mean 21) for COVID-19 vaccine hesitancy, mostly concerning vaccine safety (N=160, 47.3%). ...CONCLUSION: COVID …

RESULTS: Out of 394 participants, 221 (56%) were hesitant to receive a COVID-19 vaccine. Participants expressed several reason …

136

Axillary Lymphadenopathy After a COVID-19 Vaccine Booster Dose: Time to Resolution on Ultrasound Follow-Up and Associated Factors.

Mema E, Lane EG, Drotman MB, Eisen CS, Thomas C, Prince MR, Dodelzon K. Mema E, et al. AJR Am J Roentgenol. 2023 Aug;221(2):175-183. doi: 10.2214/AJR.22.28970. Epub 2023 Mar 8. AJR Am J Roentgenol. 2023. PMID: 36883774

BACKGROUND. Because administration of booster doses of COVID-19 vaccines is ongoing, radiologists are continuing to encounter COVID-19 vaccine-related axillary lymphadenopathy on imaging. ...CONCLUSION. Axillary lymphadenopathy after administration of a CO …

BACKGROUND. Because administration of booster doses of COVID-19 vaccines is ongoing, radiologists are continuing to encounter COVI …

137

Interruptions in bladder cancer care during the COVID-19 public health emergency.

Gore JL, Follmer K, Reynolds J, Nash M, Anderson CB, Catto JWF, Chamie K, Daneshmand S, Dickstein R, Garg T, Gilbert SM, Guzzo TJ, Kamat AM, Kates MR, Lane BR, Lotan Y, Mansour AM, Master VA, Montgomery JS, Morris DS, Nepple KG, O'Neil BB, Patel S, Pohar K, Porten SP, Riggs SB, Sankin A, Scarpato KR, Shore ND, Steinberg GD, Strope SA, Taylor JM, Comstock BA, Kessler LG, Wolff EM, Smith AB. Gore JL, et al. Urol Oncol. 2024 Apr;42(4):116.e17-116.e21. doi: 10.1016/j.urolonc.2023.11.010. Epub 2023 Dec 11. Urol Oncol. 2024. PMID: 38087711 Clinical Trial.

BACKGROUND: Academic and community urology centers participating in a pragmatic clinical trial in non-muscle-invasive bladder cancer completed monthly surveys assessing restrictions in aspects of bladder cancer care due to the COVID-19 Public Health Emergency …

BACKGROUND: Academic and community urology centers participating in a pragmatic clinical trial in non-muscle-invasive bladder cancer …

138

Side effects of COVID-19 vaccinations in patients treated for breast cancer.

Juhel BC, Brunelle CL, Bernstein MC, Smith LH, Jung AW, Ababneh HS, Hausman EK, Bucci LK, Bernstein T, Naoum GE, Taghian AG. Juhel BC, et al. Clin Exp Med. 2023 Nov;23(7):3671-3680. doi: 10.1007/s10238-023-01050-z. Epub 2023 Apr 8. Clin Exp Med. 2023. PMID: 37031282 Free PMC article.

Lymph node swelling is a side effect of the mRNA COVID-19 vaccines, a distressing side effect for women treated for breast cancer. The purpose of this study is to present side effects reported by a cohort of patients treated for breast cancer. A survey link w …

Lymph node swelling is a side effect of the mRNA COVID-19 vaccines, a distressing side effect for women treated for breast cancer …

139

mRNA COVID-19 vaccine elicits potent adaptive immune response without the acute inflammation of SARS-CoV-2 infection.

Ivanova EN, Shwetar J, Devlin JC, Buus TB, Gray-Gaillard S, Koide A, Cornelius A, Samanovic MI, Herrera A, Mimitou EP, Zhang C, Karmacharya T, Desvignes L, Ødum N, Smibert P, Ulrich RJ, Mulligan MJ, Koide S, Ruggles KV, Herati RS, Koralov SB. Ivanova EN, et al. iScience. 2023 Nov 24;26(12):108572. doi: 10.1016/j.isci.2023.108572. eCollection 2023 Dec 15. iScience. 2023. PMID: 38213787 Free PMC article.

Our study presents a comprehensive multimodal single-cell analysis of blood from COVID-19 patients and healthy volunteers receiving the SARS-CoV-2 vaccine and booster. ...B and T cell repertoire analysis revealed clonal expansion among effector cells in COVID …

Our study presents a comprehensive multimodal single-cell analysis of blood from COVID-19 patients and healthy volunteers receiving t …

140

Proceedings of the Online Conference "Vaccines and Vaccination during and Post COVID Pandemics" (7-9 December 2022).

Sokolovska L, Isaguliants M, Buonaguro FM. Sokolovska L, et al. Vaccines (Basel). 2023 Jun 29;11(7):1175. doi: 10.3390/vaccines11071175. Vaccines (Basel). 2023. PMID: 37514990 Free PMC article.

The COVID-19 pandemic put focus on various aspects of vaccine research and development. ...This report summarizes conference presentations and their discussion. Sessions covered the topics of (1) COVID-19 vaccine development, evaluation, and attitude t …

The COVID-19 pandemic put focus on various aspects of vaccine research and development. ...This report summarizes conference p …

141

Understanding caregivers' decision to vaccinate childhood cancer survivors against COVID-19.

Ilic A, Haardoerfer R, Michel G, Escoffery C, Mertens AC, Marchak JG. Ilic A, et al. Cancer Med. 2023 Dec;12(23):21354-21363. doi: 10.1002/cam4.6675. Epub 2023 Nov 8. Cancer Med. 2023. PMID: 37937725 Free PMC article.

BACKGROUND: Vaccination against COVID-19 is recommended for childhood cancer survivors (CCS). This study aimed to identify antecedents contributing to caregivers' decisions to vaccinate CCS aged 5-17 years against COVID-19 by applying the Theory of Planned Be …

BACKGROUND: Vaccination against COVID-19 is recommended for childhood cancer survivors (CCS). This study aimed to identify ant …

142

Behaviors and Advocacy Related to COVID-19 among Cancer Patients: The Health Belief Model and Opportunities for Messaging and Education.

Ledford SG, Moss JL, Alles S, Wang M, Kessler FC, Marks B, Soliman AS, Joshi MD, Lengerich EJ. Ledford SG, et al. J Cancer Educ. 2023 Oct;38(5):1690-1696. doi: 10.1007/s13187-023-02323-7. Epub 2023 Jun 20. J Cancer Educ. 2023. PMID: 37336800

Cancer patients have an increased risk of severe COVID-19 outcomes and were recommended to be vaccinated, wear a mask, practice social distancing, and increase hand hygiene. ...Perceived benefits, perceived barriers, and cues-to-action were positively associated wit …

Cancer patients have an increased risk of severe COVID-19 outcomes and were recommended to be vaccinated, wear a mask, practic …

143

Observations of COVID-19 vaccine coverage and vaccine hesitancy on COVID-19 outbreak: An American ecological study.

Bajracharya D, Jansen RJ. Bajracharya D, et al. Vaccine. 2024 Jan 12;42(2):246-254. doi: 10.1016/j.vaccine.2023.12.008. Epub 2023 Dec 15. Vaccine. 2024. PMID: 38103963

The study spans a three-year data collection period for daily hospital admissions due to COVID-19 and the daily reported cases of COVID-19 across all 50 states in the USA. In doing so, we aim to demonstrate the difference in severity of the SARS-CoV-2 pathogen among …

The study spans a three-year data collection period for daily hospital admissions due to COVID-19 and the daily reported cases of …

144

Repurposing the oncolytic virus VSV51M as a COVID-19 vaccine.

Alkayyal AA, Darwish M, Ajina R, Alabbas SY, Alotaibi MA, Alsofyani A, Bokhamseen M, Hakami M, Albaradie OA, Moglan AM, Hala S, Alsahafi AF, Zakri S, Almuzaini A, Alsharari K, Kaboha F, Taher MY, Zein HS, Alroqi F, Mahmoud AB. Alkayyal AA, et al. Front Bioeng Biotechnol. 2023 Jul 17;11:1150892. doi: 10.3389/fbioe.2023.1150892. eCollection 2023. Front Bioeng Biotechnol. 2023. PMID: 37528991 Free PMC article.

The coronavirus disease 2019 (COVID-19) pandemic imposes an urgent and continued need for the development of safe and cost-effective vaccines to induce preventive responses for limiting major outbreaks around the world. ...Moreover, the VSV51M-RBD vaccine exhibited …

The coronavirus disease 2019 (COVID-19) pandemic imposes an urgent and continued need for the development of safe and cost-effective …

145

From HPV to COVID-19 and beyond: leveraging the power of serology and standards.

Hempel HA, Kemp TJ, Roche N, Pinto LA. Hempel HA, et al. Lancet Microbe. 2023 Dec;4(12):e966-e967. doi: 10.1016/S2666-5247(23)00287-2. Epub 2023 Sep 28. Lancet Microbe. 2023. PMID: 37778361 Free article. No abstract available.

146

Extracellular Vesicles as Delivery Systems in Disease Therapy.

Picon MA, Wang L, Da Fonseca Ferreira A, Dong C, Marzouka GR. Picon MA, et al. Int J Mol Sci. 2023 Dec 5;24(24):17134. doi: 10.3390/ijms242417134. Int J Mol Sci. 2023. PMID: 38138963 Free PMC article. Review.

Upon absorption by recipient cells, EV cargo can modify the transcription machinery and alter the cellular functions of these cells, playing a role in disease pathogenesis. EVs have been tested as the delivery system for the mRNA COVID-19 vaccine. Recently, differen …

Upon absorption by recipient cells, EV cargo can modify the transcription machinery and alter the cellular functions of these cells, playing …

147

Estimating the impact of COVID-19 vaccine inequities: a modeling study.

Gozzi N, Chinazzi M, Dean NE, Longini IM Jr, Halloran ME, Perra N, Vespignani A. Gozzi N, et al. Nat Commun. 2023 Jun 6;14(1):3272. doi: 10.1038/s41467-023-39098-w. Nat Commun. 2023. PMID: 37277329 Free PMC article.

Access to COVID-19 vaccines on the global scale has been drastically hindered by structural socio-economic disparities. Here, we develop a data-driven, age-stratified epidemic model to evaluate the effects of COVID-19 vaccine inequities in twenty lower middle …

Access to COVID-19 vaccines on the global scale has been drastically hindered by structural socio-economic disparities. Here, we deve …

148

Response Rate of the Third and Fourth Doses of the BNT162b2 Vaccine Administered to Cancer Patients Undergoing Active Anti-Neoplastic Treatments.

Agbarya A, Sarel I, Ziv-Baran T, Schwartz O, Shechtman Y, Kozlener E, Khoury R, Sheikh-Ahmad M, Saiegh L, Swaid F, Ahmad AA, Janzic U, Brenner R. Agbarya A, et al. Diseases. 2023 Sep 26;11(4):128. doi: 10.3390/diseases11040128. Diseases. 2023. PMID: 37873772 Free PMC article.

The BNT162b2 vaccine is globally used for preventing morbidity and mortality related to COVID-19. Cancer patients have had priority for receiving the vaccine due to their diminished immunity. ...

The BNT162b2 vaccine is globally used for preventing morbidity and mortality related to COVID-19. Cancer patients have …

149

Guillain-Barre syndrome and COVID-19 vaccines: focus on adenoviral vectors.

Rzymski P. Rzymski P. Front Immunol. 2023 Apr 26;14:1183258. doi: 10.3389/fimmu.2023.1183258. eCollection 2023. Front Immunol. 2023. PMID: 37180147 Free PMC article.

The increased risk of Guillain-Barre syndrome (GBS) has been reported for selected adenoviral vector vaccines but not for other vaccine types, including more widely used mRNA preparations. Therefore, it is unlikely that GBS results from the cross-reactivity of antibodies a …

The increased risk of Guillain-Barre syndrome (GBS) has been reported for selected adenoviral vector vaccines but not for other vaccine …

150

Serological response and immune-related adverse events following COVID-19 vaccination in cancer patients treated with immune checkpoint inhibitors: A systematic review and meta-analysis.

Wang Y, Chen D, Pan Y, Li H, Zhao W, Lu T, Kong W, Ding M, Wang X, Zhang G. Wang Y, et al. Rev Med Virol. 2024 Jan;34(1):e2495. doi: 10.1002/rmv.2495. Epub 2023 Nov 28. Rev Med Virol. 2024. PMID: 38017632 Review.

With the popularity of Coronavirus disease 2019 (COVID-19) vaccine and the development of vaccination strategies, the impact of COVID-19 vaccine on cancer patients receiving immune checkpoint inhibitors (ICIs) is still unclear. ...Cancer …

With the popularity of Coronavirus disease 2019 (COVID-19) vaccine and the development of vaccination strategies, the impact o …

151

COVID-19 Vaccine Uptake Among Students in Public Institutions of Higher Education in Arkansas in 2021.

Zohoori N, Barsotti T, Porter A, Brown C, Amick BC 3rd, Cima M, Gandy J, Markham M. Zohoori N, et al. Public Health Rep. 2023 Aug 23:333549231192464. doi: 10.1177/00333549231192464. Online ahead of print. Public Health Rep. 2023. PMID: 37610163

OBJECTIVE: Disparities in COVID-19 vaccine coverage among college students are not well studied. ...Novel approaches for tailored messaging and interventions to facilitate vaccine uptake may be needed for groups such as non-Hispanic Black students and student …

OBJECTIVE: Disparities in COVID-19 vaccine coverage among college students are not well studied. ...Novel approaches for tailo …

152

Examining protective effects of SARS-CoV-2 neutralizing antibodies after vaccination or monoclonal antibody administration.

Follmann D, O'Brien MP, Fintzi J, Fay MP, Montefiori D, Mateja A, Herman GA, Hooper AT, Turner KC, Chan KC, Forleo-Neto E, Isa F, Baden LR, El Sahly HM, Janes H, Doria-Rose N, Miller J, Zhou H, Dang W, Benkeser D, Fong Y, Gilbert PB, Marovich M, Cohen MS. Follmann D, et al. Nat Commun. 2023 Jun 17;14(1):3605. doi: 10.1038/s41467-023-39292-w. Nat Commun. 2023. PMID: 37330602 Free PMC article. Clinical Trial.

In this work, nAb titers were assessed as correlates of protection against COVID-19 in the casirivimab + imdevimab monoclonal antibody (mAb) prevention trial (ClinicalTrials.gov #NCT4452318) and in the mRNA-1273 vaccine trial (ClinicalTrials.gov #NCT04470427). ...Th …

In this work, nAb titers were assessed as correlates of protection against COVID-19 in the casirivimab + imdevimab monoclonal antibod …

153

Predictors of SARS-CoV-2 Infection and Severe and Lethal COVID-19 after Three Years of Follow-Up: A Population-Wide Study.

Flacco ME, Acuti Martellucci C, Soldato G, Di Martino G, Rosso A, Carota R, De Benedictis M, Di Marco G, Di Luzio R, Ricci M, Caponetti A, Gori D, Manzoli L. Flacco ME, et al. Viruses. 2023 Aug 24;15(9):1794. doi: 10.3390/v15091794. Viruses. 2023. PMID: 37766201 Free PMC article.

Cox proportional hazard analysis was used to compute the relative hazards of infection and severe or lethal COVID-19, adjusting for age, gender, vaccine status, hypertension, diabetes, major cardiovascular diseases (CVD), chronic obstructive pulmonary disease (COPD) …

Cox proportional hazard analysis was used to compute the relative hazards of infection and severe or lethal COVID-19, adjusting for a …

154

Vaccine-induced immune thrombotic thrombocytopenia: what do we know hitherto?

Roytenberg R, García-Sastre A, Li W. Roytenberg R, et al. Front Med (Lausanne). 2023 May 16;10:1155727. doi: 10.3389/fmed.2023.1155727. eCollection 2023. Front Med (Lausanne). 2023. PMID: 37261122 Free PMC article. Review.

Vaccine-induced immune thrombotic thrombocytopenia (VITT), also known as thrombosis with thrombocytopenia syndrome, is a catastrophic and life-threatening reaction to coronavirus disease 2019 (COVID-19) vaccines, which occurs disproportionately in response to vaccin …

Vaccine-induced immune thrombotic thrombocytopenia (VITT), also known as thrombosis with thrombocytopenia syndrome, is a catastrophic …

155

Comparative Analysis of De Novo Immune Thrombocytopenia Following mRNA COVID-19 Vaccine Versus Non-mRNA Vaccines and COVID-19: A Global Database Analysis.

Mericliler M. Mericliler M. Cureus. 2023 Jul 6;15(7):e41460. doi: 10.7759/cureus.41460. eCollection 2023 Jul. Cureus. 2023. PMID: 37546093 Free PMC article.

This study aims to investigate the incidence of de novo ITP following the mRNA COVID-19 vaccine in comparison to other non-mRNA vaccines and COVID-19. ...The occurrence of de novo ITP following COVID-19 was significantly higher compared to that followi …

This study aims to investigate the incidence of de novo ITP following the mRNA COVID-19 vaccine in comparison to other non-mRN …

156

Impact of the COVID-19 pandemic on cancer patients in western Pennsylvania: rural-urban disparities.

Demanelis K, Rosenzweig M, Robertson LB, Low CA, Daniels S, Abujaradeh H, Simon B, Bovbjerg DH, Diergaarde B. Demanelis K, et al. Cancer Causes Control. 2023 Jul;34(7):595-609. doi: 10.1007/s10552-023-01696-w. Epub 2023 May 2. Cancer Causes Control. 2023. PMID: 37129763 Free PMC article.

The COVID-19 pandemic may have impacted concerns related to care and personal health differently in rural cancer patients. ...The following patient concerns related to the pandemic were evaluated: threat of COVID-19 to their health, pandemic-related distress, …

The COVID-19 pandemic may have impacted concerns related to care and personal health differently in rural cancer patients. ... …

157

In Vitro Transcribed RNA-Based Platform Vaccines: Past, Present, and Future.

Perenkov AD, Sergeeva AD, Vedunova MV, Krysko DV. Perenkov AD, et al. Vaccines (Basel). 2023 Oct 16;11(10):1600. doi: 10.3390/vaccines11101600. Vaccines (Basel). 2023. PMID: 37897003 Free PMC article. Review.

mRNA was discovered in 1961, but it was not used as a vaccine until after three decades. Recently, the development of mRNA vaccine technology gained great impetus from the pursuit of vaccines against COVID-19. ...This discussion will facilitate the decision-m …

mRNA was discovered in 1961, but it was not used as a vaccine until after three decades. Recently, the development of mRNA vaccine …

158

Comparison of immunogenicity for Sinovac-CoronaVac vaccine vs. natural infection during cancer treatment.

Çakır E, Saydan D, Gülbagcı B, Özen M, Uğurlu I, Demirci A, Bilir F, Hacıbekiroglu I, Yıldız N, Akcali S, Altindis M, Varım C, Yaylaci S, Bilir C. Çakır E, et al. Eur Rev Med Pharmacol Sci. 2023 May;27(9):4309-4315. doi: 10.26355/eurrev_202305_32341. Eur Rev Med Pharmacol Sci. 2023. PMID: 37203857 Free article.

OBJECTIVE: Efficacy of the COVID-19 vaccines in cancer patients, especially during their active treatment, are lacking. ...Our study investigated Sinovac-CoronaVac COVID-19 vaccine immunogenicity and compared it with natural COVID-19 disease in …

OBJECTIVE: Efficacy of the COVID-19 vaccines in cancer patients, especially during their active treatment, are lacking. ...Our …

159

COVID-19 Vaccine Uptake in Patients with Multiple Myeloma and AL Amyloidosis: A Cross-Sectional Observational Study from India.

Ganju P, Kalaiyarasi JP, Karunakaran P, Veeraiah S, Mehra N. Ganju P, et al. Indian J Hematol Blood Transfus. 2024 Jan;40(1):30-35. doi: 10.1007/s12288-023-01680-z. Epub 2023 Jul 22. Indian J Hematol Blood Transfus. 2024. PMID: 38312195

COVID-19 vaccine uptake has been comparable, if not higher, in LMICs (Low- and Middle-Income Countries) than in developed nations. ...Vaccine-related side effects were mild and no vaccine-related thrombotic events were seen. ...

COVID-19 vaccine uptake has been comparable, if not higher, in LMICs (Low- and Middle-Income Countries) than in developed nati …

160

Parents' Intentions, Concerns and Information Needs about COVID-19 Vaccination in New Jersey: A Qualitative Analysis.

Kohler RE, Wagner RB, Careaga K, Vega J, Btoush R, Greene K, Kantor L. Kohler RE, et al. Vaccines (Basel). 2023 Jun 13;11(6):1096. doi: 10.3390/vaccines11061096. Vaccines (Basel). 2023. PMID: 37376485 Free PMC article.

BACKGROUND: In 2019, the World Health Organization identified vaccine hesitancy as a top ten global health threat, which has been exacerbated by the COVID-19 pandemic. ...Most of the parents described that their adolescents had received at least one dose of a COV …

BACKGROUND: In 2019, the World Health Organization identified vaccine hesitancy as a top ten global health threat, which has been exa …

161

COVID-19 vaccine uptake among patients undergoing treatment for lung cancer: A cross-sectional study in India.

Suri TM, Ghosh T, Singhal S, Arunachalam M, Alwani H, Mohan A. Suri TM, et al. Lung India. 2023 May-Jun;40(3):294-296. doi: 10.4103/lungindia.lungindia_539_22. Lung India. 2023. PMID: 37148035 Free PMC article. No abstract available.

162

What is the optimal country for minimum COVID-19 morbidity and mortality rates?

Arbel Y, Arbel Y, Kerner A, Kerner M. Arbel Y, et al. Environ Sci Pollut Res Int. 2023 May;30(21):59212-59232. doi: 10.1007/s11356-023-26632-y. Epub 2023 Mar 31. Environ Sci Pollut Res Int. 2023. PMID: 37000395 Free PMC article.

Despite the remarkable progress in genetic sequencing and subsequent vaccine development, the world continues to grapple with the ominous threats of rapidly appearing SARS-CoV-2 variants. ...Referring to the COVID-19 scope of mortality, the lowest likelihood is obta …

Despite the remarkable progress in genetic sequencing and subsequent vaccine development, the world continues to grapple with the omi …

163

Safety and efficacy of Sinopharm vaccine (BBIBP-CorV) in elderly population of Faisalabad district of Pakistan.

Nadeem I, Ul Munamm SA, Ur Rasool M, Fatimah M, Abu Bakar M, Rana ZK, Khatana UF, Jordon L, Saqlain M, Mahdi N, McLoughlin H. Nadeem I, et al. Postgrad Med J. 2023 Jun 8;99(1171):463-469. doi: 10.1136/postgradmedj-2022-141649. Postgrad Med J. 2023. PMID: 37294716

The Drug Regulatory Authority of Pakistan gave emergency approval for Sinopharm (BBIBP-CorV) COVID-19 vaccine in December 2021. The phase 3 trial of BBIBP-CorV included only 612 participants aged 60 years and above. ...CONCLUSION: Our study showed that BBIBP-CorV …

The Drug Regulatory Authority of Pakistan gave emergency approval for Sinopharm (BBIBP-CorV) COVID-19 vaccine in December 2021 …

164

Longitudinal data on humoral response and neutralizing antibodies against SARS-CoV-2 Omicron BA.1 and subvariants BA.4/5 and BQ.1.1 after COVID-19 vaccination in cancer patients.

Overheu O, Lendowski S, Quast DR, Kühn D, Vidal Blanco E, Kraeft AL, Steinmann E, Kourti E, Lugnier C, Steinmann J, Reinacher-Schick A, Pfaender S. Overheu O, et al. J Cancer Res Clin Oncol. 2023 Sep;149(12):10633-10644. doi: 10.1007/s00432-023-04961-2. Epub 2023 Jun 10. J Cancer Res Clin Oncol. 2023. PMID: 37300723 Free PMC article.

METHODS: Cancer patients at our center were prospectively enrolled between 01/2021 and 02/2022. ...CONCLUSION: We present the first data on nAb against BQ.1.1 following the third vaccination in cancer patients. Our results highlight the threat that new emerging SARS …

METHODS: Cancer patients at our center were prospectively enrolled between 01/2021 and 02/2022. ...CONCLUSION: We present the first d …

165

Sending a Message: Use of mRNA Vaccines to Target the Tumor Immune Microenvironment.

Ramirez F, Zambrano A, Hennis R, Holland N, Lakshmanaswamy R, Chacon J. Ramirez F, et al. Vaccines (Basel). 2023 Sep 7;11(9):1465. doi: 10.3390/vaccines11091465. Vaccines (Basel). 2023. PMID: 37766141 Free PMC article. Review.

Indeed, major breakthroughs in mRNA vaccine technology, such as the use of replacement nucleotides and lipid nanoparticle delivery, led to the vital success of mRNA vaccine technology in fighting COVID-19. ...To this end, we also review current mRNA cancer …

Indeed, major breakthroughs in mRNA vaccine technology, such as the use of replacement nucleotides and lipid nanoparticle delivery, l …

166

Recent Advances in Messenger Ribonucleic Acid (mRNA) Vaccines and Their Delivery Systems: A Review.

Yihunie W, Nibret G, Aschale Y. Yihunie W, et al. Clin Pharmacol. 2023 Aug 3;15:77-98. doi: 10.2147/CPAA.S418314. eCollection 2023. Clin Pharmacol. 2023. PMID: 37554660 Free PMC article. Review.

Messenger ribonucleic acid (mRNA) was found as the intermediary that transfers genetic information from DNA to ribosomes for protein synthesis in 1961. The emergency use authorization of the two covid-19 mRNA vaccines, BNT162b2 and mRNA-1273, is a significant achievement i …

Messenger ribonucleic acid (mRNA) was found as the intermediary that transfers genetic information from DNA to ribosomes for protein synthes …

167

Prostate-specific antigen level association with COVID-19 infection and vaccination.

Frumer M, Aharony SM, Shoshany O, Kedar D, Baniel J, Golan S. Frumer M, et al. Clin Genitourin Cancer. 2023 Dec;21(6):e405-e411. doi: 10.1016/j.clgc.2023.05.001. Epub 2023 May 5. Clin Genitourin Cancer. 2023. PMID: 37270370 Free PMC article.

INTRODUCTION: The associations among SARS-CoV-2 infection, vaccination and total serum prostate serum antigen (PSA) levels in men undergoing screening for prostate cancer are unknown. METHODS: A retrospective analysis of data from a large health maintenance organization. . …

INTRODUCTION: The associations among SARS-CoV-2 infection, vaccination and total serum prostate serum antigen (PSA) levels in men undergoing …

168

The Influence of the COVID-19 Pandemic on Colorectal Cancer Secondary Preventive Healthcare Measures.

Bărbulescu LN, Rădulescu VM, Bărbulescu LF, Mogoantă SȘ. Bărbulescu LN, et al. Healthcare (Basel). 2023 Sep 3;11(17):2457. doi: 10.3390/healthcare11172457. Healthcare (Basel). 2023. PMID: 37685491 Free PMC article.

The rise of COVID-19 significantly negatively impacted the number of patients adhering to the pilot colorectal cancer screening and the number of test results during the pandemic period. ...We observed that screening participation was associated with vaccination (78 …

The rise of COVID-19 significantly negatively impacted the number of patients adhering to the pilot colorectal cancer screenin …

169

COVID-19 vaccine reactogenicity among participants enrolled in the GENCOV study.

Morgan G, Casalino S, Chowdhary S, Frangione E, Fung CYJ, Lapadula E, Arnoldo S, Bearss E, Binnie A, Borgundvaag B, Briollais L, Dagher M, Devine L, Friedman SM, Khan Z, Mighton C, Nirmalanathan K, Richardson D, Stern S, Taher A, Wolday D, Lerner-Ellis J, Taher J. Morgan G, et al. Vaccine. 2024 Apr 19;42(11):2733-2739. doi: 10.1016/j.vaccine.2024.03.030. Epub 2024 Mar 23. Vaccine. 2024. PMID: 38521677

BACKGROUND: GENCOV is a prospective, observational cohort study of COVID-19-positive adults. Here, we characterize and compare side effects between COVID-19 vaccines and determine whether reactogenicity is exacerbated by prior SARS-CoV-2 infection. METHODS: Particip …

BACKGROUND: GENCOV is a prospective, observational cohort study of COVID-19-positive adults. Here, we characterize and compare side e …

170

Knowledge, attitudes, concern, behaviors, and barriers associated with the readiness to receive seasonal influenza vaccine among healthcare workers in oncology setting during the COVID-19 pandemic.

Mubarak S, AlGhawrie H, Qaddumi B. Mubarak S, et al. Hum Vaccin Immunother. 2023 Aug 1;19(2):2251836. doi: 10.1080/21645515.2023.2251836. Hum Vaccin Immunother. 2023. PMID: 37635299 Free PMC article.

These vaccination rates showed a significant increase despite the challenges posed by the COVID-19 pandemic. Furthermore, 89.1% of the participants expressed their intention to receive the vaccine in the autumn of 2021. ...This study demonstrates a high rate of infl …

These vaccination rates showed a significant increase despite the challenges posed by the COVID-19 pandemic. Furthermore, 89.1% of th …

171

High-dimensional analysis of 16 SARS-CoV-2 vaccine combinations reveals lymphocyte signatures correlating with immunogenicity.

Nuñez NG, Schmid J, Power L, Alberti C, Krishnarajah S, Kreutmair S, Unger S, Blanco S, Konigheim B, Marín C, Onofrio L, Kienzler JC, Costa-Pereira S, Ingelfinger F; InmunoCovidCba; InViV working group; Pasinovich ME, Castelli JM, Vizzotti C, Schaefer M, Villar-Vesga J, Mundt S, Merten CH, Sethi A, Wertheimer T, Lutz M, Vanoaica D, Sotomayor C, Gruppi A, Münz C, Cardozo D, Barbás G, Lopez L, Carreño P, Castro G, Raboy E, Gallego S, Morón G, Cervi L, Acosta Rodriguez EV, Maletto BA, Maccioni M, Becher B. Nuñez NG, et al. Nat Immunol. 2023 Jun;24(6):941-954. doi: 10.1038/s41590-023-01499-w. Epub 2023 Apr 24. Nat Immunol. 2023. PMID: 37095378 Free PMC article.

Priming with the inactivated-virus vaccine increased the SARS-CoV-2-specific T cell response, whereas boosting did not. ...These data provide a framework for improving future vaccine strategies against pathogens and cancer....

Priming with the inactivated-virus vaccine increased the SARS-CoV-2-specific T cell response, whereas boosting did not. ...These data …

172

Investigating the association between the COVID-19 vaccination and incident gastrointestinal symptomology: A comprehensive dataset.

Houston KD, Hartnett J, Rose SJ. Houston KD, et al. Data Brief. 2023 Jun;48:109287. doi: 10.1016/j.dib.2023.109287. Epub 2023 Jun 1. Data Brief. 2023. PMID: 37287691 Free PMC article.

The best protection against infection is through receipt of the COVID-19 vaccine, which is associated with a low incidence of adverse events. ...Data analysis included reporting of demographic variables as well as descriptive statistics regarding side effects experi …

The best protection against infection is through receipt of the COVID-19 vaccine, which is associated with a low incidence of …

173

Monovalent SARS-COV-2 mRNA vaccine using optimal UTRs and LNPs is highly immunogenic and broadly protective against Omicron variants.

Ye Z, Bonam SR, McKay LGA, Plante JA, Walker J, Zhao Y, Huang C, Chen J, Xu C, Li Y, Liu L, Harmon J, Gao S, Song D, Zhang Z, Plante KS, Griffiths A, Chen J, Hu H, Xu Q. Ye Z, et al. Proc Natl Acad Sci U S A. 2023 Dec 26;120(52):e2311752120. doi: 10.1073/pnas.2311752120. Epub 2023 Dec 22. Proc Natl Acad Sci U S A. 2023. PMID: 38134199 Free PMC article.

The emergence of highly transmissible severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants of concern (VOCs) that are resistant to the current COVID-19 vaccines highlights the need for continued development of broadly protective vaccines for the future. .. …

The emergence of highly transmissible severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants of concern (VOCs) that are resis …

174

COVID-19 Antibody Seroconversion in Cancer Patients: Impact of Therapy Cessation-A Single-Center Study.

Souan L, Abdel-Razeq H, Nashwan S, Al Badr S, Alrabi K, Sughayer MA. Souan L, et al. Vaccines (Basel). 2023 Oct 30;11(11):1659. doi: 10.3390/vaccines11111659. Vaccines (Basel). 2023. PMID: 38005991 Free PMC article.

BACKGROUND: The effective development of COVID-19 vaccination has mitigated its harm. Using two laboratory methods, we investigated the efficacy of the BNT162b2 mRNA and BBIBP-CorV COVID-19 vaccines on seroconversion rates in cancer patients undergoing active …

BACKGROUND: The effective development of COVID-19 vaccination has mitigated its harm. Using two laboratory methods, we investigated t …

175

Responses of patients with cancer to mRNA vaccines depend on the time interval between vaccination and last treatment.

Donhauser LV, Veloso de Oliveira J, Schick C, Manlik W, Styblova S, Lutzenberger S, Aigner M, Philipp P, Robert S, Gandorfer B, Hempel D, Hempel L, Zehn D. Donhauser LV, et al. J Immunother Cancer. 2023 Sep;11(9):e007387. doi: 10.1136/jitc-2023-007387. J Immunother Cancer. 2023. PMID: 37730271 Free PMC article.

BACKGROUND: Personalized mRNA vaccines are promising new therapeutic options for patients with cancer. Because mRNA vaccines are not yet approved for first-line therapy, the vaccines are presently applied to individuals that received prior therapies that can have immunocom …

BACKGROUND: Personalized mRNA vaccines are promising new therapeutic options for patients with cancer. Because mRNA vaccines are not …

176

Timing of BNT162b2 vaccine prior to COVID-19 infection, influence disease severity in patients with hematologic malignancies: Results from a cohort study.

Gutwein O, Herzog Tzarfati K, Apel A, Rahimi-Levene N, Ilana L, Tadmor T, Koren-Michowitz M. Gutwein O, et al. Cancer Med. 2023 Nov;12(21):20503-20510. doi: 10.1002/cam4.6397. Epub 2023 Oct 25. Cancer Med. 2023. PMID: 37877352 Free PMC article.

Emergence of COVID-19 variants, availability of vaccine boosters and antiviral treatments could impact their outcome. ...Diagnosis of chronic lymphocytic leukemia (CLL) was significantly associated with severe COVID-19 (p = 0.01). The vaccine effective …

Emergence of COVID-19 variants, availability of vaccine boosters and antiviral treatments could impact their outcome. ...Diagn …

177

Comment on "SARS-CoV-2 vaccine safety and COVID-19 risk perception in hematopoietic stem cell transplant recipients".

Mungmunpuntipantip R, Wiwanitkit V. Mungmunpuntipantip R, et al. Support Care Cancer. 2023 Dec 22;32(1):51. doi: 10.1007/s00520-023-08237-w. Support Care Cancer. 2023. PMID: 38129605 No abstract available.

178

Retrospective Analysis of Equity-Based Optimization for COVID-19 Vaccine Allocation.

Stafford E, Dimitrov D, Ceballos R, Campelia G, Matrajt L. Stafford E, et al. medRxiv [Preprint]. 2023 May 11:2023.05.08.23289679. doi: 10.1101/2023.05.08.23289679. medRxiv. 2023. PMID: 37214988 Free PMC article. Updated. Preprint.

Marginalized racial and ethnic groups in the United States were disproportionally affected by the COVID-19 pandemic. To study these disparities, we construct an age-and-race-stratified mathematical model of SARS-CoV-2 transmission fitted to age-and-race-stratified data fro …

Marginalized racial and ethnic groups in the United States were disproportionally affected by the COVID-19 pandemic. To study these d …

179

Compliance with Influenza Vaccination and Cervical, Breast, and Colorectal Cancer Screening in a Sample of Women in Puerto Rico: Community Engagement Efforts from PR-CEAL.

Hill K, Pérez CM, Pons-Calvo A, Canales-Birriel K, López-Cepero A, Solís-Torres N, Tamarit-Quevedo Z, Colón-López V. Hill K, et al. P R Health Sci J. 2023 Dec;42(4):318-321. P R Health Sci J. 2023. PMID: 38104289

Therefore, prevention and early detection of these cancer types are critical to reducing morbidity and mortality. This study assessed whether women who received the influenza vaccine had increased adherence to cervical, breast, and colorectal cancer screening …

Therefore, prevention and early detection of these cancer types are critical to reducing morbidity and mortality. This study assessed …

180

Multimodal single-cell datasets characterize antigen-specific CD8⁺ T cells across SARS-CoV-2 vaccination and infection.

Zhang B, Upadhyay R, Hao Y, Samanovic MI, Herati RS, Blair JD, Axelrad J, Mulligan MJ, Littman DR, Satija R. Zhang B, et al. Nat Immunol. 2023 Oct;24(10):1725-1734. doi: 10.1038/s41590-023-01608-9. Epub 2023 Sep 21. Nat Immunol. 2023. PMID: 37735591 Free PMC article.

Here, we used multimodal sequencing technologies to perform a longitudinal analysis of circulating human leukocytes collected before and after immunization with the mRNA vaccine BNT162b2. Our data indicated distinct subpopulations of CD8(+) T cells, which reliably appeared …

Here, we used multimodal sequencing technologies to perform a longitudinal analysis of circulating human leukocytes collected before and aft …

181

COVID-19 Vaccine Booster Hesitancy among Hispanic Adults: A Cross-Sectional Study from the Puerto Rico Community Engagement Alliance against COVID-19 Disparities (PR-CEAL).

Berríos H, López-Cepero A, Pérez CM, Cameron S, Pons Calvo AD, Colón-López V. Berríos H, et al. Vaccines (Basel). 2023 Aug 28;11(9):1426. doi: 10.3390/vaccines11091426. Vaccines (Basel). 2023. PMID: 37766103 Free PMC article.

This study aimed to assess health belief correlates of COVID-19 vaccine booster uptake. Using a convenience sampling approach, the Puerto Rico-Community Engagement Alliance (PR-CEAL) conducted a cross-sectional study where 787 participants were recruited using onlin …

This study aimed to assess health belief correlates of COVID-19 vaccine booster uptake. Using a convenience sampling approach, …

182

The value of serum neutralizing antibody in evaluating predictability of COVID-19 after recovery and the validation of vaccine.

Guo B, Li Z, Fu G, Li H, Yang J, Zhang Z, Wu L, Wang J. Guo B, et al. BMC Infect Dis. 2023 Dec 20;23(1):895. doi: 10.1186/s12879-023-08465-9. BMC Infect Dis. 2023. PMID: 38124038 Free PMC article.

CONCLUSIONS: Nabs showed a regular change in the course of coronavirus disease 2019 (COVID-19). The detection of Nabs is very important for monitoring the course of COVID-19 and predicting the strength of antibody protection....

CONCLUSIONS: Nabs showed a regular change in the course of coronavirus disease 2019 (COVID-19). The detection of Nabs is very importa …

183

Iron deficiency and the effectiveness of the BNT162b2 vaccine for SARS-CoV-2 infection: A retrospective, longitudinal analysis of real-world data.

Tene L, Karasik A, Chodick G, Pereira DIA, Schou H, Waechter S, Göhring UM, Drakesmith H. Tene L, et al. PLoS One. 2023 May 22;18(5):e0285606. doi: 10.1371/journal.pone.0285606. eCollection 2023. PLoS One. 2023. PMID: 37216375 Free PMC article.

BACKGROUND: Iron plays a key role in human immune responses; however, the influence of iron deficiency on the coronavirus disease 2019 (COVID-19) vaccine effectiveness is unclear. AIM: To assess the effectiveness of the BNT162b2 messenger RNA COVID-19 vacc …

BACKGROUND: Iron plays a key role in human immune responses; however, the influence of iron deficiency on the coronavirus disease 2019 (C …

184

The Global Demand and Supply Balance of the Human Papillomavirus Vaccine: Implications for the Global Strategy for the Elimination of Cervical Cancer.

Malvolti S, Soble A, Bloem P, LaMontagne DS, Aggarwal R, Pitisuttithum P, Rees H, Cernuschi T. Malvolti S, et al. Vaccines (Basel). 2023 Dec 19;12(1):4. doi: 10.3390/vaccines12010004. Vaccines (Basel). 2023. PMID: 38276663 Free PMC article.

Using a population-based forecasting methodology and leveraging the WHO's yearly vaccine supply data collection, we updated global demand and supply projections for the HPV vaccine for the period of 2022-2031. ...In the long term, HPV supply will be more than suffic …

Using a population-based forecasting methodology and leveraging the WHO's yearly vaccine supply data collection, we updated global de …

185

Immunogenicity and Safety of Booster SARS-CoV-2 mRNA Vaccine Dose in Allogeneic Hematopoietic Stem Cell Transplantation Recipients.

Mittal A, Solera JT, Ferreira VH, Kothari S, Kimura M, Pasic I, Mattsson JI, Humar A, Kulasingam V, Ierullo M, Kumar D, Hosseini-Moghaddam SM. Mittal A, et al. Transplant Cell Ther. 2023 Nov;29(11):706.e1-706.e7. doi: 10.1016/j.jtct.2023.08.008. Epub 2023 Aug 13. Transplant Cell Ther. 2023. PMID: 37582470

The primary outcome was to determine the quantitative anti-receptor-binding domain (RBD) antibody titers after the fourth dose of the COVID-19 vaccine. The secondary outcomes included adverse effects and all-cause mortality. This single-group prospective cohort incl …

The primary outcome was to determine the quantitative anti-receptor-binding domain (RBD) antibody titers after the fourth dose of the COV …

186

Safety, immunogenecity and effectiveness of ChAdOx1 nCoV-19 vaccine during the second wave of pandemic in India: a real-world study.

Chavan P, Dey R, Castelino R, Kamble A, Poladia P, Bagal R, Jadhav M, Shirsat A, Chavan A, Dhumal S, Kumar S, Krishnamurty MN, Bhat V, Bhattacharjee A, Gota V. Chavan P, et al. Drug Metab Pers Ther. 2023 Apr 26;38(3):227-236. doi: 10.1515/dmpt-2022-0150. eCollection 2023 Sep 1. Drug Metab Pers Ther. 2023. PMID: 37098129 Free article.

OBJECTIVES: This real-world study was conducted to assess the adverse effects following immunization (AEFI) and immunogenicity of ChAdO1 nCoV-19 vaccine in terms of neutralising antibody titers and to study the effects of covariates such as age, sex, comorbidities and prio …

OBJECTIVES: This real-world study was conducted to assess the adverse effects following immunization (AEFI) and immunogenicity of ChAdO1 nCo …

187

[(18)F]FES PET Resolves the Diagnostic Dilemma of COVID-19-Vaccine-Associated Hypermetabolic Lymphadenopathy in ER-Positive Breast Cancer.

Nogami M, Tsujikawa T, Maeda H, Kosaka N, Takahashi M, Kinoshita N, Mori T, Makino A, Kiyono Y, Murakami T, Goi T, Okazawa H. Nogami M, et al. Diagnostics (Basel). 2023 May 25;13(11):1851. doi: 10.3390/diagnostics13111851. Diagnostics (Basel). 2023. PMID: 37296702 Free PMC article.

Coronavirus disease (COVID-19) vaccination is known to cause a diagnostic dilemma due to false-positive findings on [(18)F]FDG PET in vaccine-associated hypermetabolic lymphadenopathy. We present two case reports of women with estrogen-receptor (ER)-positive canc …

Coronavirus disease (COVID-19) vaccination is known to cause a diagnostic dilemma due to false-positive findings on [(18)F]FDG PET in …

188

Addressing COVID-19 vaccine hesitancy in rural community pharmacies: a protocol for a stepped wedge randomized clinical trial.

Curran G, Mosley C, Gamble A, Painter J, Ounpraseuth S, Brewer NT, Teeter B, Smith M, Halladay J, Hughes T, Shepherd JG, Hastings T, Simpson K, Carpenter D. Curran G, et al. Implement Sci. 2023 Dec 18;18(1):72. doi: 10.1186/s13012-023-01327-7. Implement Sci. 2023. PMID: 38110979 Free PMC article.

COVID-19 vaccine hesitancy is associated with lower uptake, which translates to higher susceptibility to SARS-CoV-2 variants in communities where vaccination coverage is low. ...ASORT teaches pharmacists how to identify persons eligible for COVID-19 vaccinati …

COVID-19 vaccine hesitancy is associated with lower uptake, which translates to higher susceptibility to SARS-CoV-2 variants i …

189

What We Learned about the Feasibility of Gene Electrotransfer for Vaccination on a Model of COVID-19 Vaccine.

Kamensek U, Cemazar M, Kranjc Brezar S, Jesenko T, Kos S, Znidar K, Markelc B, Modic Z, Komel T, Gorse T, Rebersek E, Jakopic H, Sersa G. Kamensek U, et al. Pharmaceutics. 2023 Jul 19;15(7):1981. doi: 10.3390/pharmaceutics15071981. Pharmaceutics. 2023. PMID: 37514166 Free PMC article.

DNA vaccination is one of the emerging approaches for a wide range of applications, including prophylactic vaccination against infectious diseases and therapeutic vaccination against cancer. The aim of this study was to evaluate the feasibility of our previously optimized …

DNA vaccination is one of the emerging approaches for a wide range of applications, including prophylactic vaccination against infectious di …

190

Prospective assessment of humoral and cellular immune responses to a 3rd COVID-19 mRNA vaccine dose among immunocompromised individuals.

Haidar G, Hodges JC, Bilderback A, Lukanski A, Linstrum K, Postol B, Troyan R, Wisniewski MK, Coughenour L, Heaps A, Jacobs JL, Hughes Kramer K, Klamar-Blain C, Kohl J, Liang W, Morris B, Macatangay BJC, Parikh UM, Sobolewksi MD, Musgrove C, Crandall MD, Mahon J, Mulvey K, Collins K, King AC, Wells A, Zapf R, Agha M, Minnier T, Angus DC, Mellors JW. Haidar G, et al. J Infect Dis. 2023 Nov 16:jiad511. doi: 10.1093/infdis/jiad511. Online ahead of print. J Infect Dis. 2023. PMID: 37972260

BACKGROUND: Improved COVID-19 prevention is needed for immunocompromised individuals. ...

191

Advancing personalized medicine in brain cancer: exploring the role of mRNA vaccines.

Lin F, Lin EZ, Anekoji M, Ichim TE, Hu J, Marincola FM, Jones LD, Kesari S, Ashili S. Lin F, et al. J Transl Med. 2023 Nov 18;21(1):830. doi: 10.1186/s12967-023-04724-0. J Transl Med. 2023. PMID: 37978542 Free PMC article. Review.

The mRNA platform offers advantages of rapid development, high potency, cost-effectiveness, and safety. This review provides an overview of mRNA vaccine delivery technologies, tumor antigen identification, combination therapies, and recent therapeutic outcomes, with a part …

The mRNA platform offers advantages of rapid development, high potency, cost-effectiveness, and safety. This review provides an overview of …

192

Human Papillomavirus Vaccine Awareness and Acceptability for Primary Prevention of Cervical Cancer in Pakistan: A Cross-Sectional Study.

Shamsi U, Zahid F, Abdul Jabbar AB, Musharraf MD, Gauhar F, Akbar I, Sherwani M, Bhatti WK, Chaudhary EUH, Sadiq S, Shaikh AN, Shaikh F. Shamsi U, et al. Asian Pac J Cancer Prev. 2024 Mar 1;25(3):813-820. doi: 10.31557/APJCP.2024.25.3.813. Asian Pac J Cancer Prev. 2024. PMID: 38546064 Free article.

BACKGROUND: Human papillomavirus (HPV) vaccine is the most effective option for primary prevention HPV, a well-known cause of cervical cancer. ...Mass awareness campaigns about HPV, HPV vaccine, and cervical cancer are needed to increase the acceptabil …

BACKGROUND: Human papillomavirus (HPV) vaccine is the most effective option for primary prevention HPV, a well-known cause of cervica …

193

Retrospective analysis of equity-based optimization for COVID-19 vaccine allocation.

Stafford E, Dimitrov D, Ceballos R, Campelia G, Matrajt L. Stafford E, et al. PNAS Nexus. 2023 Sep 9;2(9):pgad283. doi: 10.1093/pnasnexus/pgad283. eCollection 2023 Sep. PNAS Nexus. 2023. PMID: 37693211 Free PMC article.

Marginalized racial and ethnic groups in the United States were disproportionally affected by the COVID-19 pandemic. To study these disparities, we construct an age-and-race-stratified mathematical model of SARS-CoV-2 transmission fitted to age-and-race-stratified data fro …

Marginalized racial and ethnic groups in the United States were disproportionally affected by the COVID-19 pandemic. To study these d …

194

Booster effect of a third mRNA-based COVID-19 vaccine dose in patients with myeloid malignancies.

Mori A, Onozawa M, Kobayashi M, Tsukamoto S, Senjo H, Ishio T, Yokoyama E, Kanaya M, Izumiyama K, Saito M, Muraki H, Morioka M, Teshima T, Kondo T. Mori A, et al. Cancer Med. 2023 Aug;12(16):16881-16888. doi: 10.1002/cam4.6314. Epub 2023 Jul 6. Cancer Med. 2023. PMID: 37409608 Free PMC article.

AIMS: In this complementary study, we investigated the booster effect of a third mRNA-based COVID-19 vaccine dose in patients with myeloid malignancies. MATERIALS & METHODS: A total 58 patients including 20 patients with MDS and 38 patients with AML were enrolle …

AIMS: In this complementary study, we investigated the booster effect of a third mRNA-based COVID-19 vaccine dose in patients …

195

RNA nanotechnology: A new chapter in targeted therapy.

Lv T, Meng Y, Liu Y, Han Y, Xin H, Peng X, Huang J. Lv T, et al. Colloids Surf B Biointerfaces. 2023 Oct;230:113533. doi: 10.1016/j.colsurfb.2023.113533. Epub 2023 Sep 6. Colloids Surf B Biointerfaces. 2023. PMID: 37713955 Review.

Furthermore, the utilization of lipid nanoparticles loaded with novel coronavirus antigen mRNA to control the COVID-19 pandemic has led to a notable surge in research on nanoparticle vaccines. ...In light of this, we conducted a comprehensive review of the research advance …

Furthermore, the utilization of lipid nanoparticles loaded with novel coronavirus antigen mRNA to control the COVID-19 pandemic has l …

196

Adenovirus vector and mRNA vaccines: Mechanisms regulating their immunogenicity.

Provine NM, Klenerman P. Provine NM, et al. Eur J Immunol. 2023 Jun;53(6):e2250022. doi: 10.1002/eji.202250022. Epub 2022 Nov 20. Eur J Immunol. 2023. PMID: 36330560 Free PMC article. Review.

Replication-incompetent adenovirus (Ad) vector and mRNA-lipid nanoparticle (LNP) constructs represent two modular vaccine platforms that have attracted substantial interest over the past two decades. ...This review will synthesize our current knowledge of the specific mech …

Replication-incompetent adenovirus (Ad) vector and mRNA-lipid nanoparticle (LNP) constructs represent two modular vaccine platforms t …

197

Ethno-demographic disparities in humoral responses to the COVID-19 vaccine among healthcare workers.

Ahluwalia P, Vashisht A, Singh H, Sahajpal NS, Mondal AK, Jones K, Farmaha J, Bloomquist R, Carlock CM, Fransoso D, Sun C, Day T, Prah C, Vuong T, Ray P, Bradshaw D, Galvis MM, Fulzele S, Raval G, Moore JX, Cortes J, James JN, Kota V, Kolhe R. Ahluwalia P, et al. J Med Virol. 2023 Sep;95(9):e29067. doi: 10.1002/jmv.29067. J Med Virol. 2023. PMID: 37675796

The COVID-19 pandemic had a profound impact on global health, but rapid vaccine administration resulted in a significant decline in morbidity and mortality rates worldwide. ...A total of 290 HCWs were included and assessed prospectively in this study. COVID s …

The COVID-19 pandemic had a profound impact on global health, but rapid vaccine administration resulted in a significant decli …

198

Nanoformulations targeting immune cells for cancer therapy: mRNA therapeutics.

Yang W, Cao J, Cheng H, Chen L, Yu M, Chen Y, Cui X. Yang W, et al. Bioact Mater. 2023 May;23:438-470. doi: 10.1016/j.bioactmat.2022.11.014. Epub 2022 Dec 1. Bioact Mater. 2023. PMID: 36471724 Free PMC article.

The approved worldwide use of two messenger RNA (mRNA) vaccines (BNT162b2 and mRNA-1273) in late 2020 has proven the remarkable success of mRNA therapeutics together with lipid nanoformulation technology in protecting people against coronaviruses during COVID-19 pandemic. …

The approved worldwide use of two messenger RNA (mRNA) vaccines (BNT162b2 and mRNA-1273) in late 2020 has proven the remarkable success of m …

199

Views about vaccines and how views changed during the COVID-19 pandemic among a national sample of young gay, bisexual, and other men who have sex with men.

Marshall D, McRee AL, Gower AL, Reiter PL. Marshall D, et al. Hum Vaccin Immunother. 2023 Dec 15;19(3):2281717. doi: 10.1080/21645515.2023.2281717. Epub 2023 Nov 15. Hum Vaccin Immunother. 2023. PMID: 37965729 Free PMC article.

We examined perceptions of vaccines and changes during the coronavirus disease 2019 (COVID-19) pandemic. From 2019 to 2021, a national sample of young gay, bisexual, and other men who have sex with men completed an open-ended survey item about vaccine perceptions. A …

We examined perceptions of vaccines and changes during the coronavirus disease 2019 (COVID-19) pandemic. From 2019 to 2021, a nationa …

200

Application of Traditional Vaccine Development Strategies to SARS-CoV-2.

Rando HM, Lordan R, Lee AJ, Naik A, Wellhausen N, Sell E, Kolla L; COVID-19 Review Consortium; Gitter A, Greene CS. Rando HM, et al. mSystems. 2023 Apr 27;8(2):e0092722. doi: 10.1128/msystems.00927-22. Epub 2023 Mar 2. mSystems. 2023. PMID: 36861991 Free PMC article. Review.

Sell, et al., mSystems 8:e00928-22, 2023, https://doi.org/10.1128/mSystems.00928-22), we review the more recent and novel development of nucleic acid-based vaccine technologies. We further consider the role that these COVID-19 vaccine development programs hav …

Sell, et al., mSystems 8:e00928-22, 2023, https://doi.org/10.1128/mSystems.00928-22), we review the more recent and novel development of nuc …

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

847 results

Results by year

Search Page

Filters

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

Search Results

847 results

Results by year